Biotech Industry Financials, Performance and Ratios
-
Industry Score
42.6 /100
Rank 88 out of 131 Industries -
Advance/Decline
126/166
-
No. of Companies292
-
Avg. Market Cap2,100
-
Price to Earning Ratio2.88
-
Price to Earning Growth Ratio0.19
-
Price to Book Ratio12.55
-
Return on Equity35.75
-
Return on Capital Employed-
-
Return on Assets4.49
-
Dividend yield 1 year %0.35 %
-
Net Profit Growth Annual YoY %-32.80 %
-
Net Profit Growth Qtr YoY %22.60 %
-
Net Profit Growth Qtr QoQ %-74.84 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Elanco Animal Health Inc |
|
9,275.5
|
18.7
|
L
 -2.0%
H
18.6
19.1
|
L
 1.7%
H
17.1
19.1
|
L
 12%
H
16.9
19.1
|
L
 34.3%
H
13.2
19.1
|
L
 23.7%
H
8.0
19.1
|
L
 32.9%
H
7.9
19.1
|
L
 -33.6%
H
7.9
37.5
|
L
H
7.9
37.6
|
Nuvation Bio Inc Ordinary |
|
1,122.7
|
3.3
|
L
 -6.0%
H
3.3
3.6
|
L
 10.4%
H
2.9
4.1
|
L
 42.6%
H
2.2
4.1
|
L
 32.3%
H
1.6
4.1
|
L
 17.6%
H
1.5
4.1
|
L
 15.9%
H
1.0
4.2
|
L
 -68.7%
H
1.0
15.2
|
L
H
1.0
15.2
|
Arcus Biosciences Inc |
|
1,201.6
|
11.3
|
L
 -1.3%
H
11.1
11.4
|
L
 6.6%
H
10.6
12.2
|
L
 24.6%
H
8.9
12.2
|
L
 13.2%
H
7.9
12.2
|
L
 -28.2%
H
6.5
19.0
|
L
 -56.1%
H
6.5
36.1
|
L
 -45.5%
H
6.5
49.1
|
L
H
6.3
49.1
|
Whitehawk Therapeutics Inc |
|
85.3
|
1.8
|
L
 1.1%
H
1.8
1.9
|
L
 0.6%
H
1.8
1.9
|
L
 3.4%
H
1.6
1.9
|
L
 -3.2%
H
1.6
2.2
|
L
 -1.1%
H
1.4
3.8
|
L
 -85.9%
H
1.2
14.8
|
L
 -90.3%
H
1.2
49.8
|
L
H
1.2
101.3
|
AbCellera Biologics Inc |
|
1,234.2
|
4.1
|
L
 -1.0%
H
4.1
4.2
|
L
 -1.2%
H
3.8
4.3
|
L
 -2.8%
H
3.8
4.8
|
L
 69.3%
H
2.5
5.8
|
L
 72.8%
H
1.9
5.8
|
L
 -63.5%
H
1.9
15.0
|
L
H
1.9
71.9
|
L
H
1.9
71.9
|
Arcellx Inc |
|
3,950.3
|
71.2
|
L
 0.2%
H
70.1
71.9
|
L
 2.7%
H
67
73.1
|
L
 1.0%
H
66.5
74.7
|
L
 4.6%
H
60.9
74.9
|
L
 0.0%
H
47.9
107.4
|
L
 256.2%
H
16.7
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
Adma Biologics Inc |
|
3,889.7
|
16.3
|
L
 -0.7%
H
16.1
16.7
|
L
 -5.6%
H
16.1
17.4
|
L
 -1.3%
H
15.8
17.9
|
L
 -20.9%
H
14.6
22.4
|
L
 0.3%
H
13.5
25.7
|
L
 469.9%
H
2.2
25.7
|
L
 614.9%
H
1.0
25.7
|
L
 83.1%
H
1.0
25.7
|
Adaptive Biotechnologies Corp |
|
1,915.6
|
12.6
|
L
 0.3%
H
12.4
12.7
|
L
 -4.6%
H
12.4
13.3
|
L
 3.1%
H
11.9
13.5
|
L
 24.7%
H
9.9
13.5
|
L
 194.6%
H
4.0
13.5
|
L
 37.6%
H
2.3
13.5
|
L
 -65.3%
H
2.3
71.3
|
L
H
2.3
71.3
|
Aditxt Inc |
|
4.9
|
1.0
|
L
 7.6%
H
0.9
1.0
|
L
 -3.9%
H
0.9
1.1
|
L
 -16.8%
H
0.9
1.2
|
L
 -35.7%
H
0.8
2.2
|
L
 -94.7%
H
0.0
21.2
|
L
 -100.0%
H
0.0
45584
|
L
 -100.0%
H
0.0
538400
|
L
H
0.0
766400
|
Agenus Inc |
|
146.9
|
4.6
|
L
 8.2%
H
4.3
4.7
|
L
 10.3%
H
4.1
4.7
|
L
 -4.0%
H
4.1
4.8
|
L
 -22.5%
H
4.1
7.3
|
L
 -6.9%
H
1.4
7.3
|
L
 -91.0%
H
1.4
196
|
L
 -94.1%
H
1.4
196
|
L
 -96.7%
H
1.4
196
|
Aeglea BioTherapeutics Inc |
|
67.3
|
16.6
|
L
 -2.2%
H
16.5
17.1
|
L
 0.9%
H
16.1
17.6
|
L
 9.7%
H
14.7
17.8
|
L
 -2%
H
13.9
19.2
|
L
 9.6%
H
13.9
19.2
|
L
 33.0%
H
2.7
39
|
L
 -90.9%
H
2.7
247.5
|
L
H
2.7
318.8
|
Avalon GloboCare Corp |
|
9.5
|
2.5
|
L
 5.1%
H
2.3
2.6
|
L
 22.8%
H
2.0
2.6
|
L
 11.7%
H
1.9
2.6
|
L
 -27.3%
H
1.9
4.7
|
L
 629.4%
H
0.2
11.7
|
L
 -54.7%
H
0.2
11.7
|
L
 -79.7%
H
0.2
16.5
|
L
H
0.2
135
|
Aldeyra Therapeutics Inc |
|
341.1
|
5.7
|
L
 -0.4%
H
5.6
5.8
|
L
 -2.7%
H
5.4
5.9
|
L
 8.0%
H
5.0
6.2
|
L
 113.5%
H
2.6
6.2
|
L
 -7.3%
H
1.1
7.2
|
L
 -14.1%
H
1.1
12.0
|
L
 -3.6%
H
1.1
16.0
|
L
 -20.7%
H
1.1
16.7
|
Alector Inc |
|
284.4
|
2.8
|
L
 1.8%
H
2.7
2.9
|
L
 19.6%
H
2.3
3.1
|
L
 30.7%
H
2.0
3.1
|
L
 88.6%
H
1.3
3.1
|
L
 -42.1%
H
0.9
6.4
|
L
 -74.4%
H
0.9
10.4
|
L
 -77.5%
H
0.9
43.3
|
L
H
0.9
43.3
|
Allogene Therapeutics Inc |
|
246.3
|
1.1
|
L
 -2.6%
H
1.1
1.1
|
L
 -1.8%
H
1.1
1.2
|
L
 6.7%
H
1.0
1.3
|
L
 -21.8%
H
1.0
1.7
|
L
 -53.9%
H
0.9
3.8
|
L
 -92.8%
H
0.9
15.6
|
L
 -96.6%
H
0.9
44.9
|
L
H
0.9
55
|
Altimmune Inc |
|
327.4
|
3.7
|
L
H
3.7
3.8
|
L
 -3.1%
H
3.5
3.8
|
L
 7.5%
H
3.3
3.9
|
L
 -34.0%
H
2.9
7.7
|
L
 -40.2%
H
2.9
11.2
|
L
 -80.8%
H
2.1
21.6
|
L
 -70.7%
H
2.1
24.6
|
L
 -99.2%
H
1.5
1050
|
Alvotech |
|
2,508.4
|
8.1
|
L
 -1.4%
H
8.0
8.2
|
L
 -0.3%
H
7.9
8.4
|
L
 -4.9%
H
7.8
9.1
|
L
 -24.5%
H
7.8
10.8
|
L
 -27.4%
H
7.4
13.7
|
L
 1.6%
H
5.5
18
|
L
H
5.2
18
|
L
H
5.2
18
|
Kalaris Therapeutics Inc |
|
86.0
|
4.6
|
L
 -0.9%
H
4.4
4.7
|
L
 12.8%
H
3.8
7.3
|
L
 72.3%
H
2.1
7.3
|
L
 39.4%
H
2.1
7.3
|
L
 505.3%
H
0.4
12.9
|
L
 -46.3%
H
0.4
12.9
|
L
 -80.1%
H
0.4
49.0
|
L
H
0.4
49.0
|
Amgen |
|
151,548.9
|
281.5
|
L
 0.5%
H
278.8
282.1
|
L
 -2.2%
H
277.3
288.7
|
L
 -2.3%
H
277.3
301.5
|
L
 -3.0%
H
267.8
311.3
|
L
 -12.2%
H
253.3
339.2
|
L
 14.7%
H
211.7
346.9
|
L
 16.7%
H
198.6
346.9
|
L
 82.1%
H
130.1
346.9
|
AnaptysBio Inc |
|
618.5
|
22.1
|
L
 -0.4%
H
21.9
22.3
|
L
 8.8%
H
20.4
23.0
|
L
 5.1%
H
19.5
23.0
|
L
 -6.7%
H
19.2
28.5
|
L
 -38.4%
H
12.2
40.7
|
L
 -16.9%
H
12.2
41.3
|
L
 38.8%
H
12.2
41.3
|
L
H
10
134
|
ANI Pharmaceuticals Inc |
|
2,094.1
|
96.6
|
L
 1.4%
H
95.2
96.9
|
L
 3.3%
H
93.2
96.9
|
L
 18.5%
H
81.4
96.9
|
L
 55.8%
H
61.2
96.9
|
L
 59.6%
H
52.5
96.9
|
L
 156.7%
H
30.5
96.9
|
L
 232.9%
H
22.3
96.9
|
L
 79.0%
H
22.3
96.9
|
Anixa Biosciences Inc |
|
95.3
|
3.0
|
L
 -0.7%
H
3.0
3.0
|
L
 -1%
H
2.9
3.2
|
L
 -0.7%
H
2.9
3.2
|
L
 7.3%
H
2.9
3.8
|
L
 -7.8%
H
2.1
4.2
|
L
 -28.8%
H
2.1
6.5
|
L
 55.8%
H
1.9
8.1
|
L
 -29.0%
H
0.6
8.1
|
AN2 Therapeutics Inc |
|
31.4
|
1.2
|
L
 -3.4%
H
1.1
1.2
|
L
 4.6%
H
1.1
1.3
|
L
 6.5%
H
1.1
1.3
|
L
 1.8%
H
1.0
1.3
|
L
 12.8%
H
1.0
1.7
|
L
 -86.3%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
Applied Dna Sciences Inc |
|
3.0
|
2.3
|
L
H
2.3
2.4
|
L
 -28.8%
H
2.1
3.3
|
L
 -45.7%
H
2.1
4.3
|
L
 -56.8%
H
2.1
6.0
|
L
 -99.8%
H
0.7
1410
|
L
 -100.0%
H
0.7
48000
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
5820000
|
Aptevo Therapeutics Inc |
|
5.0
|
1.5
|
L
 3.4%
H
1.5
1.6
|
L
 -6.7%
H
1.5
1.7
|
L
 -32.3%
H
1.5
2.2
|
L
 -69.1%
H
1.5
13.1
|
L
 -99.4%
H
1.5
381.5
|
L
 -100.0%
H
1.5
234432
|
L
 -100.0%
H
1.5
1953600
|
L
H
1.5
3778913.6
|
AquaBounty Technologies Inc |
|
4.6
|
1.2
|
L
 -4.8%
H
1.2
1.3
|
L
 0.9%
H
1.0
1.5
|
L
 58.7%
H
0.7
1.6
|
L
 50.6%
H
0.7
1.6
|
L
 21.4%
H
0.5
1.6
|
L
 -94.7%
H
0.5
23.8
|
L
 -98.4%
H
0.5
266.4
|
L
H
0.5
610
|
Arvinas Inc |
|
589.5
|
8.0
|
L
 1.1%
H
7.8
8.1
|
L
 3.9%
H
7.5
8.2
|
L
 27.7%
H
6.3
8.2
|
L
 6.6%
H
6.1
8.3
|
L
 -67.1%
H
5.9
29.6
|
L
 -83.4%
H
5.9
58.0
|
L
 -67.6%
H
5.9
108.5
|
L
H
5.9
108.5
|
Arrowhead Pharmaceuticals Inc |
|
3,800.7
|
27.5
|
L
 1.2%
H
27.2
27.8
|
L
 24.8%
H
22.7
29.3
|
L
 67.4%
H
15.8
29.3
|
L
 63.5%
H
14.3
29.3
|
L
 23.7%
H
9.6
29.3
|
L
 -29.8%
H
9.6
42.5
|
L
 -22.5%
H
9.6
93.7
|
L
 401.6%
H
1.2
93.7
|
Athira Pharma Inc |
|
15.0
|
0.4
|
L
H
0.4
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 -2.6%
H
0.4
0.4
|
L
 5.6%
H
0.3
0.5
|
L
 -29.6%
H
0.2
0.8
|
L
 -88.9%
H
0.2
4.4
|
L
H
0.2
34.8
|
L
H
0.2
34.8
|
Aurinia Pharmaceuticals Inc |
|
1,616.4
|
12.3
|
L
 -0.2%
H
12.2
12.4
|
L
 2.4%
H
11.6
12.8
|
L
 8%
H
11.2
12.8
|
L
 49.9%
H
7.3
12.8
|
L
 69.2%
H
6.4
12.8
|
L
 80.1%
H
4.1
12.8
|
L
 -11.7%
H
4.1
34.0
|
L
 254.9%
H
1.4
34.0
|
Aura Biosciences Inc |
|
386.4
|
6.2
|
L
 -3.9%
H
6.2
6.5
|
L
 -0.6%
H
6.2
6.6
|
L
 -8.5%
H
6.1
7.4
|
L
 -4.3%
H
5.9
7.5
|
L
 -20.1%
H
4.3
12.4
|
L
 -60.4%
H
4.3
19.2
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
Tectonic Therapeutic Inc |
|
319.2
|
17.1
|
L
 4.6%
H
15.9
17.4
|
L
 -33.2%
H
15.3
19.8
|
L
 -23.5%
H
15.3
27.3
|
L
 -26.0%
H
15.3
27.3
|
L
 -7.1%
H
13.7
61.1
|
L
 61.2%
H
1.4
61.1
|
L
 -91.2%
H
1.4
240.8
|
L
H
1.4
644.4
|
Jade Biosciences Inc |
|
248.3
|
7.6
|
L
 1.7%
H
7.2
7.6
|
L
 -3.7%
H
7.2
8.1
|
L
 1.6%
H
6.7
8.4
|
L
 5.8%
H
6.6
11.3
|
L
 -88.6%
H
6.6
105
|
L
 -98.8%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
Anavex Life Sciences |
|
866.7
|
10.1
|
L
 7.9%
H
9.5
10.3
|
L
 4.7%
H
9.1
10.3
|
L
 -8.9%
H
9.1
11.7
|
L
 22.0%
H
7.9
14.0
|
L
 95.9%
H
4.9
14.4
|
L
 1.2%
H
3.3
15.2
|
L
 165.5%
H
3.3
31.5
|
L
 86.9%
H
1.3
31.5
|
Axsome Therapeutics Inc |
|
6,312.5
|
126.5
|
L
 -2.2%
H
123.5
130
|
L
 4.3%
H
120.7
130
|
L
 20.7%
H
102.7
130
|
L
 13.0%
H
96.1
130
|
L
 35.8%
H
75.6
139.1
|
L
 106.7%
H
38.9
139.1
|
L
 81.8%
H
19.4
139.1
|
L
H
1.9
139.1
|
Aziyo Biologics Inc Ordinary |
|
-
|
1.9
|
L
H
1.9
2.0
|
L
 -17.5%
H
1.9
2.4
|
L
 -6.5%
H
1.9
2.4
|
L
 -1.1%
H
1.7
2.6
|
L
 9.3%
H
1.6
2.6
|
L
 -74.2%
H
1.1
9.0
|
L
H
1.1
18.2
|
L
H
1.1
18.2
|
Adaptimmune Therapeutics Plc |
|
13.3
|
0.1
|
L
 25%
H
0.0
0.1
|
L
 -16.7%
H
0.0
0.1
|
L
 -37.5%
H
0.0
0.1
|
L
 -82.1%
H
0.0
0.4
|
L
 -95.4%
H
0.0
1.2
|
L
 -97.5%
H
0.0
2.7
|
L
 -99.4%
H
0.0
10.9
|
L
 -99.6%
H
0.0
14.8
|
Akari Therapeutics Plc ADR |
|
27.1
|
0.8
|
L
 -2.4%
H
0.8
0.9
|
L
 9.2%
H
0.6
0.9
|
L
 -16.2%
H
0.6
1.1
|
L
 -32.5%
H
0.6
1.3
|
L
 -75%
H
0.6
3.9
|
L
 -96.1%
H
0.6
22
|
L
 -97.4%
H
0.6
84.2
|
L
 -99.8%
H
0.6
738.8
|
Autolus Therapeutics plc ADR |
|
369.9
|
1.4
|
L
 -2.8%
H
1.4
1.4
|
L
 -7.3%
H
1.4
1.6
|
L
 -40.3%
H
1.4
2.5
|
L
 -40.6%
H
1.4
2.7
|
L
 -65.3%
H
1.1
5
|
L
 -55.7%
H
1.1
7.5
|
L
 -88.9%
H
1.1
14.4
|
L
H
1.1
53.2
|
BridgeBio Pharma Inc |
|
10,221.8
|
53.5
|
L
 -1.5%
H
52.3
54.5
|
L
 3.3%
H
49.8
54.6
|
L
 14.8%
H
46.3
54.6
|
L
 38.5%
H
38.6
54.6
|
L
 74.2%
H
21.7
54.6
|
L
 373.6%
H
6.6
54.6
|
L
 66.6%
H
5.0
73.5
|
L
H
5.0
73.5
|
BioAtla Inc |
|
38.2
|
0.7
|
L
 6.6%
H
0.6
0.7
|
L
 41.3%
H
0.4
0.7
|
L
 85.7%
H
0.3
0.7
|
L
 35.4%
H
0.3
0.7
|
L
 -62.6%
H
0.2
2.5
|
L
 -92.8%
H
0.2
11.7
|
L
H
0.2
76.6
|
L
H
0.2
76.6
|
BioCardia Inc |
|
12.2
|
2.1
|
L
 0.5%
H
2.1
2.1
|
L
 6.1%
H
1.9
2.1
|
L
 17.3%
H
1.7
2.1
|
L
 -3.2%
H
1.7
2.5
|
L
 -7.5%
H
1.6
3.3
|
L
 -92.4%
H
1.6
43.8
|
L
 -93.5%
H
1.6
129
|
L
 -98.4%
H
1.6
2073.6
|
Biocryst Pharmaceuticals Inc |
|
1,698.3
|
8.1
|
L
 -1.2%
H
8.0
8.2
|
L
 -2.7%
H
8.0
8.5
|
L
 -2.5%
H
8.0
8.7
|
L
 -26.7%
H
7.9
11.2
|
L
 1.4%
H
6.0
11.3
|
L
 -41.1%
H
4.0
14.5
|
L
 126.0%
H
3.3
20.0
|
L
 -33.4%
H
1.4
20.0
|
BriaCell Therapeutics Corp |
|
14.0
|
8
|
L
 0.3%
H
7.9
8.0
|
L
 3.0%
H
7.6
8.8
|
L
 -88.8%
H
7.3
79
|
L
 -97.7%
H
7.3
360
|
L
 -99.3%
H
7.3
2940
|
L
 -99.9%
H
7.3
12435
|
L
 -99.9%
H
7.3
18526.5
|
L
 -100.0%
H
7.3
138373.2
|
Black Diamond Therapeutics Inc |
|
175.4
|
3.1
|
L
 1.0%
H
2.9
3.2
|
L
 12%
H
2.7
3.2
|
L
 28.3%
H
2.3
3.2
|
L
 19.4%
H
2.2
3.3
|
L
 -43.0%
H
1.2
6.3
|
L
 4.8%
H
1.2
7.7
|
L
 -89.1%
H
1.2
37.8
|
L
H
1.2
46.3
|
Beam Therapeutics Inc |
|
1,984.8
|
19.6
|
L
 -1.6%
H
19.4
20.1
|
L
 19.9%
H
16.0
21.2
|
L
 11.4%
H
15.6
21.2
|
L
 5.6%
H
15.6
22.8
|
L
 -15.8%
H
13.5
35.3
|
L
 -65.6%
H
13.5
61.4
|
L
 -12.7%
H
13.5
138.5
|
L
H
13
138.5
|
Biogen |
|
20,888.2
|
142.5
|
L
 0.8%
H
140.5
142.9
|
L
 7.8%
H
133.5
145.3
|
L
 9.0%
H
127.7
145.3
|
L
 7.0%
H
121.1
145.3
|
L
 -29.1%
H
110.0
204.2
|
L
 -31.5%
H
110.0
319.8
|
L
 -47.0%
H
110.0
468.6
|
L
 -49.9%
H
110.0
468.6
|
BioVie Inc |
|
13.1
|
1.7
|
L
 -3.3%
H
1.7
1.8
|
L
 14.5%
H
1.5
1.9
|
L
 4.2%
H
1.4
1.9
|
L
 -83.9%
H
1.4
12.1
|
L
 -93.0%
H
1.4
75
|
L
 -99.4%
H
1.4
1438
|
L
 -99.9%
H
1.4
4609.8
|
L
 -99.9%
H
1.4
5625
|
Biomarin Pharmaceutical Inc |
|
10,670.3
|
55.6
|
L
 -1.4%
H
55.1
56.5
|
L
 -4.6%
H
55.1
59.8
|
L
 -3.1%
H
55.1
59.8
|
L
 -1.9%
H
53.7
64.0
|
L
 -33.9%
H
52.9
85.6
|
L
 -40.3%
H
52.9
117.8
|
L
 -25.4%
H
52.9
117.8
|
L
 -58.1%
H
52.9
134.7
|
Bionano Genomics Inc |
|
19.8
|
4.2
|
L
 -0.9%
H
4.2
4.3
|
L
 11.9%
H
3.6
4.4
|
L
 45.0%
H
2.9
4.4
|
L
 12.5%
H
2.9
4.4
|
L
 859.1%
H
0.1
11.6
|
L
 -83.0%
H
0.1
30.1
|
L
 -14.4%
H
0.1
156.9
|
L
H
0.1
156.9
|
Benitec Biopharma Inc |
|
367.5
|
14
|
L
 1.2%
H
13.7
14.0
|
L
 5.7%
H
13.1
14.3
|
L
 18.6%
H
11.1
14.3
|
L
 -12.5%
H
10.5
17.2
|
L
 55.2%
H
8.1
17.2
|
L
 4.5%
H
1.9
17.2
|
L
 -86.3%
H
1.9
178.3
|
L
 -99.2%
H
1.9
1876.8
|
Bon Natural Life |
|
6.8
|
1.8
|
L
 16.9%
H
1.8
3.4
|
L
 27.7%
H
1.4
3.4
|
L
 37.4%
H
1.3
3.4
|
L
 9.1%
H
1.2
3.4
|
L
 -95.7%
H
1.1
73.8
|
L
 -99.6%
H
1.1
645
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
23052.5
|
BioXcel Therapeutics Inc |
|
54.0
|
3.7
|
L
 -12.3%
H
3.7
3.9
|
L
 -8.4%
H
3.4
4.3
|
L
 -8.2%
H
3.4
8.1
|
L
 101.6%
H
1.3
8.1
|
L
 574.6%
H
0.2
8.1
|
L
 -75.4%
H
0.2
34.1
|
L
 -91.2%
H
0.2
67.7
|
L
H
0.2
71.5
|
Bicycle Therapeutics Plc ADR |
|
491.4
|
7.1
|
L
 1.3%
H
6.9
7.2
|
L
 -3.9%
H
6.8
7.6
|
L
 -7.3%
H
6.8
8.1
|
L
 -17.1%
H
6.8
9.4
|
L
 -65.5%
H
6.1
28.7
|
L
 -71.8%
H
6.1
33.5
|
L
 -57.4%
H
6.1
62.1
|
L
H
6.1
62.1
|
BioNTech SE ADR |
|
24,862.0
|
103.4
|
L
 0.7%
H
102.4
104.4
|
L
 3.4%
H
99.0
114.9
|
L
 -7.4%
H
99.0
114.9
|
L
 -4.7%
H
99.0
115.5
|
L
 15.0%
H
81.2
131.5
|
L
 -29.7%
H
76.5
189.0
|
L
 72.9%
H
58.8
464
|
L
H
12.5
464
|
Cabaletta Bio Inc |
|
153.7
|
1.7
|
L
H
1.6
1.7
|
L
 15.9%
H
1.4
1.7
|
L
 23.5%
H
1.3
1.8
|
L
 -32.3%
H
1.3
2.6
|
L
 -60.6%
H
1.0
5.5
|
L
 73.2%
H
0.6
26.4
|
L
 -84.3%
H
0.6
26.4
|
L
H
0.6
26.4
|
CalciMedica Inc |
|
50.0
|
3.6
|
L
 15.9%
H
3.1
3.6
|
L
 32.6%
H
2.7
3.6
|
L
 30.7%
H
2.3
3.6
|
L
 105.8%
H
1.4
4.3
|
L
 -32.5%
H
1.4
6.0
|
L
 -74.7%
H
1
16.4
|
L
H
1
530.3
|
L
H
1
530.3
|
Tvardi Therapeutics Inc |
|
282.6
|
30.1
|
L
 1.6%
H
29.3
30.3
|
L
 0.7%
H
28.2
31.9
|
L
 26%
H
22.7
31.9
|
L
 5.8%
H
21.1
32.0
|
L
 159.8%
H
8.1
34.3
|
L
 -92.3%
H
8.1
461.2
|
L
 -94.6%
H
8.1
1067.3
|
L
 -95.7%
H
8.1
1067.3
|
Carisma Therapeutics Inc |
|
15.9
|
0.4
|
L
 -5%
H
0.3
0.4
|
L
 72.7%
H
0.3
0.6
|
L
 40.7%
H
0.2
0.6
|
L
 100%
H
0.2
1.3
|
L
 -62%
H
0.1
1.3
|
L
 -97.1%
H
0.1
13.7
|
L
 -98.0%
H
0.1
120.8
|
L
 -99.4%
H
0.1
120.8
|
Crescent Biopharma Inc |
|
-
|
12.8
|
L
 -1.4%
H
12.6
13.1
|
L
 -11.3%
H
12.6
14.7
|
L
 -0.6%
H
12.4
15.8
|
L
 51.8%
H
7.9
21.4
|
L
 12.5%
H
7.6
21.4
|
L
 167.2%
H
2.8
21.4
|
L
 12.5%
H
0.9
21.4
|
L
 -96.9%
H
0.9
412.9
|
C4 Therapeutics Inc |
|
192.2
|
2.7
|
L
 -0.4%
H
2.6
2.7
|
L
 3.9%
H
2.5
2.9
|
L
 8%
H
2.2
3.1
|
L
 56.1%
H
1.4
3.1
|
L
 -50%
H
1.1
7.2
|
L
 -75.7%
H
1.1
12.6
|
L
H
1.1
51.2
|
L
H
1.1
51.2
|
Compugen |
|
131.9
|
1.4
|
L
 -2.8%
H
1.4
1.5
|
L
H
1.4
1.5
|
L
 -6%
H
1.4
1.6
|
L
 -19.0%
H
1.4
1.8
|
L
 -23.0%
H
1.1
2.7
|
L
 38.2%
H
0.5
3.0
|
L
 -90.3%
H
0.5
18.9
|
L
 -72.6%
H
0.5
19.9
|
Cognition Therapeutics Inc |
|
216.1
|
2.5
|
L
 2.1%
H
2.4
2.5
|
L
 0.8%
H
2.3
2.7
|
L
 222.4%
H
0.8
3.8
|
L
 716.7%
H
0.3
3.8
|
L
 329.8%
H
0.2
3.8
|
L
 27.6%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
CoDiagnostics Inc |
|
11.9
|
0.3
|
L
H
0.3
0.3
|
L
 -6.1%
H
0.3
0.3
|
L
 24%
H
0.3
0.4
|
L
 3.3%
H
0.2
0.4
|
L
 -76.9%
H
0.2
1.4
|
L
 -90.4%
H
0.2
3.8
|
L
 -97.4%
H
0.2
20.7
|
L
H
0.2
31.0
|
Coeptis Therapeutics Holdings |
|
61.9
|
12.8
|
L
 -0.9%
H
12.4
13.5
|
L
 -3.6%
H
11.8
13.5
|
L
 15.1%
H
10.8
14.7
|
L
 43.5%
H
6.8
14.7
|
L
 246.1%
H
2.3
14.7
|
L
 25.9%
H
2.3
242.6
|
L
H
2.3
242.6
|
L
H
2.3
242.6
|
Cogent Biosciences Inc |
|
1,779.8
|
12.7
|
L
 0.5%
H
12.6
12.8
|
L
 5.5%
H
11.9
13.5
|
L
 16.2%
H
10.7
13.5
|
L
 87.4%
H
6.6
13.5
|
L
 21.7%
H
3.7
13.5
|
L
 -23.8%
H
3.7
17.5
|
L
 39.1%
H
3.7
18.1
|
L
H
1.2
70.6
|
Caribou Biosciences Inc |
|
165.8
|
1.8
|
L
 -1.7%
H
1.8
1.8
|
L
 -4.8%
H
1.8
2.0
|
L
 2.9%
H
1.6
2.2
|
L
 41.3%
H
1.0
2.7
|
L
 3.5%
H
0.7
3
|
L
 -85.0%
H
0.7
13.2
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
Cardiol Therapeutics Inc |
|
89.6
|
1.1
|
L
 1.9%
H
1.0
1.1
|
L
 -0.9%
H
1.0
1.2
|
L
 8.1%
H
1.0
1.4
|
L
 -24.1%
H
0.9
1.6
|
L
 -41.5%
H
0.8
2.6
|
L
 -8.5%
H
0.5
3.1
|
L
 -65.6%
H
0.5
5.3
|
L
H
0.5
8.5
|
Curis Inc |
|
21.9
|
1.8
|
L
 2.3%
H
1.7
1.8
|
L
 4.8%
H
1.6
2.0
|
L
 2.3%
H
1.5
2.0
|
L
 -26.2%
H
1.5
3.1
|
L
 -64.9%
H
1.0
6.4
|
L
 -91.3%
H
1.0
20.7
|
L
 -91.2%
H
1.0
348
|
L
 -99.3%
H
1.0
372
|
CorMedix Inc |
|
1,024.2
|
13.7
|
L
 7.6%
H
12.8
13.8
|
L
 -7.5%
H
11.6
14.9
|
L
 32.8%
H
9.9
15.0
|
L
 -1.9%
H
9.6
17.4
|
L
 138.2%
H
5.4
17.4
|
L
 275.9%
H
2.6
17.4
|
L
 211.8%
H
2.6
18.8
|
L
 9.8%
H
0.9
22.7
|
CRISPR Therapeutics AG |
|
4,785.8
|
52.6
|
L
 -2.7%
H
52
54.3
|
L
 1.5%
H
50.8
55.6
|
L
 -4.3%
H
50.8
61.4
|
L
 25.7%
H
39.8
71.1
|
L
 17.9%
H
30.0
71.1
|
L
 -20.6%
H
30.0
91.1
|
L
 -35.4%
H
30.0
220.2
|
L
H
11.6
220.2
|
Champions Oncology Inc |
|
92.8
|
6.7
|
L
 -1.0%
H
6.7
6.8
|
L
 -1.0%
H
6.6
7.3
|
L
 5.0%
H
6.1
8.2
|
L
 -2.3%
H
5.9
9.6
|
L
 58.4%
H
3.6
12.0
|
L
 -7.3%
H
3.6
12.0
|
L
 -7.4%
H
3.6
14.7
|
L
 -3.3%
H
1.1
17.9
|
Cue Biopharma Inc |
|
59.2
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 -7.2%
H
0.8
0.9
|
L
 20.3%
H
0.5
1.0
|
L
 30.5%
H
0.5
2.0
|
L
 -76.1%
H
0.5
5.1
|
L
 -95.1%
H
0.5
18.4
|
L
H
0.5
31.7
|
Cadrenal Therapeutics Inc |
|
27.0
|
13.2
|
L
 -1.5%
H
13.0
13.4
|
L
 1.6%
H
12.3
13.4
|
L
 18.1%
H
10.3
14.1
|
L
 -12.8%
H
8.7
16.0
|
L
 68.2%
H
6.9
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
Chemomab Therapeutics ADR |
|
15.9
|
3.1
|
L
 1.0%
H
3.0
3.1
|
L
 -2.2%
H
3.0
3.2
|
L
 -20.9%
H
3.0
4.1
|
L
 -42.0%
H
3.0
5.4
|
L
 -59.5%
H
3.0
9.8
|
L
 -77.7%
H
1.7
21.4
|
L
 -94.9%
H
1.7
675.2
|
L
H
1.7
736
|
Compass Pathways Plc ADR |
|
491.2
|
5.1
|
L
 2.8%
H
5.0
5.4
|
L
 15.8%
H
4.4
5.4
|
L
 16.6%
H
4.0
5.4
|
L
 6.7%
H
2.3
5.4
|
L
 -22.7%
H
2.3
7.5
|
L
 -68.3%
H
2.3
16.6
|
L
H
2.3
61.7
|
L
H
2.3
61.7
|
Denali Therapeutics Inc |
|
2,162.5
|
14.8
|
L
 -4.6%
H
14.7
15.6
|
L
 -3.1%
H
14.5
16.2
|
L
 6.0%
H
12.9
16.2
|
L
 0.6%
H
12.9
16.2
|
L
 -41.4%
H
10.6
33.3
|
L
 -53.6%
H
10.6
34.8
|
L
 -51.4%
H
10.6
93.9
|
L
H
10.6
93.9
|
Dominari Holdings Inc |
|
108.0
|
7.0
|
L
 14.1%
H
6.2
7.0
|
L
 8.3%
H
5.6
7.0
|
L
 21.3%
H
5.2
7.6
|
L
 28.7%
H
4.3
7.6
|
L
 286.1%
H
0.8
13.6
|
L
 18.4%
H
0.8
13.6
|
L
 -26.5%
H
0.8
43.4
|
L
 -99.0%
H
0.8
850.9
|
DarioHealth Corp |
|
21.9
|
9.1
|
L
 -0.8%
H
9.1
9.2
|
L
 -4%
H
8.9
10.6
|
L
 -15.5%
H
7.6
11.8
|
L
 -34.9%
H
7.6
15.1
|
L
 -45.3%
H
7.6
31
|
L
 -89.2%
H
7.6
135.6
|
L
 -97.1%
H
7.6
637
|
L
 -99.6%
H
7.6
4669.9
|
Bright Minds Biosciences Inc |
|
291.9
|
41.2
|
L
 -4.2%
H
41.2
43.0
|
L
 5.9%
H
38
46.4
|
L
 6.1%
H
37.5
46.4
|
L
 49.2%
H
23.2
46.4
|
L
 3512.3%
H
0.9
79.0
|
L
 387.3%
H
0.9
79.0
|
L
H
0.9
79.0
|
L
H
0.9
79.0
|
Design Therapeutics Inc |
|
373.6
|
6.6
|
L
 12.7%
H
5.7
6.6
|
L
 18.6%
H
5.5
6.6
|
L
 53.3%
H
4.2
6.6
|
L
 63.6%
H
3.3
6.6
|
L
 40.5%
H
2.6
7.8
|
L
 -71.8%
H
1.9
25.0
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
Precision Biosciences Inc |
|
59.8
|
5.1
|
L
 2.0%
H
4.9
5.1
|
L
 3.5%
H
4.7
5.2
|
L
 15.8%
H
4.2
5.2
|
L
 -7.7%
H
4.0
5.6
|
L
 -49.0%
H
3.6
10.7
|
L
 205.4%
H
0.3
19.4
|
L
 -4.9%
H
0.3
19.4
|
L
H
0.3
23.7
|
Dynavax Technologies Corp |
|
1,151.6
|
9.8
|
L
 1.2%
H
9.7
9.9
|
L
 -3.0%
H
9.5
10.3
|
L
 -4.9%
H
9.5
11.5
|
L
 -4.1%
H
9.5
12.1
|
L
 -11.0%
H
9.2
14.6
|
L
 -13.3%
H
9.2
15.2
|
L
 103.7%
H
3.6
21.4
|
L
 -67.3%
H
1.8
32.5
|
Dyne Therapeutics Inc |
|
1,866.5
|
13.1
|
L
 -1.4%
H
13.1
13.5
|
L
 -2.7%
H
13.0
14.3
|
L
 17.6%
H
10.8
14.3
|
L
 -10.8%
H
8.1
15.2
|
L
 -60.3%
H
6.4
37.1
|
L
 -11.9%
H
6.4
47.5
|
L
H
4.3
47.5
|
L
H
4.3
47.5
|
Editas Medicine Inc |
|
248.2
|
2.8
|
L
 -1.1%
H
2.7
2.8
|
L
 7.4%
H
2.4
2.8
|
L
 24.9%
H
2.1
3.2
|
L
 44.5%
H
1.8
3.6
|
L
 -23.1%
H
0.9
4.1
|
L
 -83.0%
H
0.9
16.3
|
L
 -90.6%
H
0.9
100.0
|
L
H
0.9
100.0
|
Elicio Therapeutics Inc |
|
186.3
|
11.4
|
L
 -2.6%
H
11.3
11.7
|
L
 8.3%
H
10.0
11.7
|
L
 23.9%
H
8.5
12.4
|
L
 45.6%
H
7.6
12.4
|
L
 169.5%
H
3.9
12.4
|
L
 11.8%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
Enliven Therapeutics Inc |
|
1,143.8
|
19.3
|
L
 -3.6%
H
19.1
19.9
|
L
 -4.7%
H
19.1
21.3
|
L
 9.2%
H
17.8
21.4
|
L
 -6.9%
H
17.4
24.4
|
L
 -9.9%
H
13.3
30.0
|
L
 125.6%
H
8
30.0
|
L
 -78.3%
H
3.9
119.7
|
L
H
3.9
250.8
|
Climb Bio Inc |
|
162.0
|
2.4
|
L
 -3.2%
H
2.4
2.6
|
L
 7.2%
H
2.1
2.6
|
L
 40.6%
H
1.6
2.6
|
L
 71.9%
H
1.2
2.6
|
L
 -67.7%
H
1.1
8.8
|
L
 -20.3%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
Enlivex Therapeutics |
|
24.3
|
1.0
|
L
 -1.9%
H
1.0
1.1
|
L
 -2.9%
H
1.0
1.1
|
L
 -28.7%
H
1.0
2.1
|
L
 5.2%
H
0.9
2.1
|
L
 -19.7%
H
0.8
2.1
|
L
 -79.1%
H
0.8
5.4
|
L
 -78.1%
H
0.8
29.4
|
L
 -99.5%
H
0.8
318
|
Enochian Biosciences Inc |
|
-
|
0.2
|
L
 -9.5%
H
0.2
0.2
|
L
 -20.8%
H
0.2
0.2
|
L
 -24%
H
0.2
0.3
|
L
 -38.7%
H
0.2
0.4
|
L
 -40.6%
H
0.2
0.5
|
L
 -90.6%
H
0.2
2.5
|
L
 -94.7%
H
0.2
13.8
|
L
 -95.3%
H
0.2
13.8
|
Ensysce Biosciences Inc |
|
6.2
|
2.1
|
L
H
2.1
2.1
|
L
 0.5%
H
2.0
2.2
|
L
 -3.7%
H
2.0
2.2
|
L
 -11.8%
H
2.0
2.5
|
L
 467.6%
H
0.1
9.9
|
L
 -97.4%
H
0.1
109.9
|
L
 -99.9%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
Equillium Inc |
|
69.3
|
1.9
|
L
 3.2%
H
1.9
2.1
|
L
 11.5%
H
1.6
2.4
|
L
 288%
H
0.8
2.4
|
L
 410.5%
H
0.3
2.4
|
L
 108.6%
H
0.3
2.4
|
L
 -12.6%
H
0.3
3.3
|
L
 -62.4%
H
0.3
11.3
|
L
H
0.3
27.1
|
Edgewise Therapeutics Inc |
|
1,580.2
|
15
|
L
 0.8%
H
14.6
15.1
|
L
 4.5%
H
14.1
15.8
|
L
 18.3%
H
12.3
15.8
|
L
 -1.6%
H
12.2
16.3
|
L
 -14.4%
H
10.6
38.1
|
L
 24.4%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
Evaxion Biotech AS ADR |
|
17.7
|
2.8
|
L
 -4.8%
H
2.7
3.0
|
L
 2.2%
H
2.5
3.0
|
L
 -0.7%
H
2.5
3.4
|
L
 -10.2%
H
2.1
3.4
|
L
 -18.6%
H
0.8
9.8
|
L
 -86.4%
H
0.8
35.2
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
Fate Therapeutics Inc |
|
109.6
|
1.0
|
L
 -2.1%
H
0.9
1.0
|
L
 -8.7%
H
0.9
1.1
|
L
 3.3%
H
0.9
1.2
|
L
 -40.6%
H
0.9
1.8
|
L
 -72.0%
H
0.7
4.2
|
L
 -96.6%
H
0.7
29.4
|
L
 -96.9%
H
0.7
121.2
|
L
 -85.0%
H
0.7
121.2
|
Forte Biosciences Inc |
|
138.1
|
11.1
|
L
 -0.2%
H
10.9
11.5
|
L
 1%
H
10.7
12
|
L
 9.1%
H
9.9
13.6
|
L
 -1.9%
H
9.1
19.6
|
L
 46.0%
H
4.1
28
|
L
 -66.1%
H
4.1
34
|
L
 -98.5%
H
4.1
1349.8
|
L
H
0.0
1349.8
|
4D Molecular Therapeutics Inc |
|
319.4
|
6.8
|
L
 -1.9%
H
6.8
7.1
|
L
 11.0%
H
6.0
7.4
|
L
 21.5%
H
5.3
7.6
|
L
 57.2%
H
3.7
7.6
|
L
 -54.6%
H
2.2
17.4
|
L
 -27.4%
H
2.2
36.3
|
L
H
2.2
55.1
|
L
H
2.2
55.1
|
Foghorn Therapeutics Inc |
|
310.9
|
5.5
|
L
 -4.4%
H
5.5
5.8
|
L
 8.7%
H
5.0
5.9
|
L
 20.1%
H
4.6
5.9
|
L
 23.3%
H
4.3
6.8
|
L
 -27.0%
H
2.9
10.2
|
L
 -46.4%
H
2.7
10.7
|
L
H
2.7
28.3
|
L
H
2.7
28.3
|
Frequency Therapeutics Inc |
|
-
|
32.9
|
L
 -0.8%
H
29.3
33.2
|
L
 42.6%
H
20.2
34.7
|
L
 105.8%
H
14.2
34.7
|
L
 125.6%
H
11.5
34.7
|
L
 117.9%
H
10.3
34.7
|
L
 -69.2%
H
9.2
279.5
|
L
 -96.3%
H
9.2
2918.5
|
L
H
9.2
2918.5
|
First Wave BioPharma Inc |
|
4.1
|
2.6
|
L
 -2.6%
H
2.6
2.7
|
L
 15.4%
H
2.1
3.0
|
L
 630.6%
H
0.5
3.0
|
L
 405.8%
H
0.4
3.0
|
L
 526.2%
H
0.4
3.0
|
L
 -99.4%
H
0.4
509.6
|
L
 -100.0%
H
0.4
110458.7
|
L
H
0.4
235200
|
Galectin Therapeutics Inc |
|
305.6
|
4.8
|
L
 2.1%
H
4.7
4.8
|
L
 11.5%
H
4.2
4.8
|
L
 14.9%
H
3.5
4.8
|
L
 261.4%
H
1.3
4.8
|
L
 93.9%
H
0.7
4.8
|
L
 155.1%
H
0.7
4.8
|
L
 80%
H
0.7
5.7
|
L
 116.8%
H
0.5
9.5
|
Gain Therapeutics Inc |
|
62.2
|
1.7
|
L
 -1.1%
H
1.7
1.8
|
L
 -13.1%
H
1.6
2.1
|
L
 16.9%
H
1.5
2.1
|
L
 -9.9%
H
1.4
2.1
|
L
 64.8%
H
1
3.2
|
L
 -57.3%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
CytoMed Therapeutics |
|
22.2
|
1.9
|
L
 3.3%
H
1.8
2.0
|
L
 -5.5%
H
1.8
2.1
|
L
 1.1%
H
1.7
2.1
|
L
 -7.8%
H
1.7
2.4
|
L
 27.7%
H
1.2
4.1
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
L
H
1.2
9.3
|
Geron Corp |
|
874.1
|
1.4
|
L
H
1.4
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 7.0%
H
1.3
1.6
|
L
 -14.4%
H
1.1
1.7
|
L
 -67.8%
H
1.1
4.8
|
L
 -49.8%
H
1.1
5.3
|
L
 -23.5%
H
1.0
5.3
|
L
 -59.5%
H
0.8
7.0
|
Gilead Sciences |
|
143,325.6
|
115.5
|
L
 -0.3%
H
113.9
116.3
|
L
 2.3%
H
111.3
116.3
|
L
 -3.3%
H
111.3
121.8
|
L
 2.7%
H
104.5
121.8
|
L
 46.7%
H
78.4
121.8
|
L
 77.4%
H
61.4
121.8
|
L
 80.1%
H
56.6
121.8
|
L
 10.1%
H
56.6
121.8
|
Greenwich LifeSciences Inc |
|
148.8
|
10.9
|
L
 -2.2%
H
10.6
11.2
|
L
 -4.9%
H
10.6
11.9
|
L
 -10.3%
H
10.6
12.8
|
L
 13.0%
H
8.6
12.9
|
L
 -24.7%
H
8.1
16.5
|
L
 16.5%
H
7.6
21.5
|
L
H
3.3
158.1
|
L
H
3.3
158.1
|
Monte Rosa Therapeutics Inc |
|
296.4
|
4.8
|
L
H
4.8
4.8
|
L
H
4.6
5.2
|
L
 9.6%
H
4.2
5.2
|
L
 -4.2%
H
4.1
6.3
|
L
 -15.6%
H
3.5
12.4
|
L
 -47.3%
H
2.4
12.4
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
Geovax Labs Inc |
|
17.5
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 -8%
H
0.7
0.8
|
L
 1.5%
H
0.7
0.8
|
L
 -38.4%
H
0.4
1.4
|
L
 -79.8%
H
0.4
3.9
|
L
 -36.7%
H
0.3
11.1
|
L
 -91.4%
H
0.3
11.1
|
L
 -100.0%
H
0.3
1000000
|
Graphite Bio Inc |
|
2,307.9
|
39.6
|
L
 -5.6%
H
39.4
42.8
|
L
 2.6%
H
38.4
42.8
|
L
 14.3%
H
34.9
42.8
|
L
 24%
H
27.8
42.8
|
L
 47.8%
H
25.9
42.8
|
L
 -76.5%
H
25.9
413
|
L
H
25.9
1666
|
L
H
25.9
1666
|
Galapagos NV ADR |
|
2,163.4
|
32.8
|
L
 -2.2%
H
32.7
33.2
|
L
 4.4%
H
30.9
33.6
|
L
 0.8%
H
30.9
33.6
|
L
 18.4%
H
26.6
33.9
|
L
 19.0%
H
22.4
33.9
|
L
 -32.4%
H
22.4
52.6
|
L
 -73.2%
H
22.4
148.7
|
L
 -44.4%
H
22.4
274.0
|
Halozyme Therapeutics Inc |
|
8,845.0
|
75.6
|
L
 -0.3%
H
74.9
76.1
|
L
 3.4%
H
71.5
76.3
|
L
 20.2%
H
62.5
76.3
|
L
 39.4%
H
51.1
76.3
|
L
 27.7%
H
42.7
76.3
|
L
 90.6%
H
29.9
76.3
|
L
 172.5%
H
25.2
76.3
|
L
 330.1%
H
7.0
76.3
|
HCW Biologics Inc |
|
7.7
|
3.6
|
L
 -6.6%
H
3.6
3.9
|
L
 -37.8%
H
3.6
5.7
|
L
 -22.9%
H
2.8
7.4
|
L
 -41.1%
H
2.8
7.4
|
L
 -87.4%
H
0.2
100.8
|
L
 -96.7%
H
0.2
111.6
|
L
H
0.2
311
|
L
H
0.2
311
|
Hillstream BioPharma Inc |
|
34.7
|
3.0
|
L
 -19.6%
H
2.9
3.6
|
L
 -50.3%
H
2.9
5.8
|
L
 140.7%
H
1.1
9.1
|
L
 96.0%
H
1.1
9.1
|
L
 122.6%
H
1.1
9.1
|
L
 -88.2%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
HilleVax Inc |
|
105.3
|
2.1
|
L
 0.5%
H
2.1
2.1
|
L
 0.5%
H
2.1
2.1
|
L
 1.9%
H
2.1
2.1
|
L
 5.5%
H
1.8
2.2
|
L
 20.7%
H
1.3
2.2
|
L
 -87.7%
H
1.3
24.4
|
L
H
1.3
24.4
|
L
H
1.3
24.4
|
Heron Therapeutics Inc |
|
203.9
|
1.3
|
L
 2.3%
H
1.3
1.4
|
L
 -1.5%
H
1.3
1.4
|
L
 0.8%
H
1.2
1.5
|
L
 -36.7%
H
1.2
2.3
|
L
 -26.1%
H
1.0
2.7
|
L
 -72.1%
H
0.5
5.1
|
L
 -91.0%
H
0.5
22.4
|
L
 -96.8%
H
0.5
42.9
|
Quantum BioPharma Ordinary |
|
48.7
|
12.8
|
L
 -1.9%
H
12.6
13.5
|
L
 -24.3%
H
12.1
17.7
|
L
 -56.4%
H
12.1
31.9
|
L
 -17.5%
H
12.1
38.3
|
L
 211.0%
H
2.7
38.3
|
L
 -78.8%
H
2.7
136.5
|
L
 -92.5%
H
2.7
288.6
|
L
H
2.7
11431.9
|
Humacyte Inc |
|
228.1
|
1.4
|
L
 2.1%
H
1.4
1.4
|
L
 -7.1%
H
1.4
1.6
|
L
 -41.9%
H
1.4
2.1
|
L
 -44.4%
H
1.4
2.8
|
L
 -72.7%
H
1.2
6.8
|
L
 -69.0%
H
1.2
10.0
|
L
H
1.2
17.5
|
L
H
1.2
17.5
|
Immucell Corp |
|
58.8
|
6.5
|
L
 -0.9%
H
6.4
6.5
|
L
 1.6%
H
6.2
7
|
L
 -2.4%
H
5.9
7.0
|
L
 -0.5%
H
5.5
7.6
|
L
 62.9%
H
3.3
7.6
|
L
 -15.4%
H
3.3
8.6
|
L
 25%
H
3.3
13.2
|
L
 -7.0%
H
3.3
13.2
|
InflaRx NV |
|
107.0
|
1.6
|
L
H
1.6
1.7
|
L
 -1.3%
H
1.5
1.8
|
L
 97.5%
H
0.8
1.8
|
L
 90.4%
H
0.7
1.8
|
L
 4.0%
H
0.7
2.8
|
L
 -41.0%
H
0.7
7.3
|
L
 -57.6%
H
0.7
7.3
|
L
H
0.7
53.1
|
ImageneBio Inc |
|
102.3
|
9.2
|
L
 -1.5%
H
9.1
9.4
|
L
 -31.7%
H
8.0
14.0
|
L
 -37.6%
H
8.0
15.3
|
L
 -46.3%
H
8.0
18
|
L
 -54.9%
H
8.0
23.3
|
L
 -85.9%
H
8.0
91.7
|
L
H
8.0
451.3
|
L
H
8.0
451.3
|
Illumina Inc |
|
14,964.2
|
97.4
|
L
 -0.8%
H
97.0
98.5
|
L
 -2.6%
H
93.9
100.8
|
L
 3.0%
H
93.9
103.7
|
L
 17.8%
H
82.6
111
|
L
 -21.7%
H
68.7
156.7
|
L
 -53.0%
H
68.7
248.9
|
L
 -71.4%
H
68.7
555.8
|
L
 -50.9%
H
68.7
555.8
|
Immunome Inc |
|
770.3
|
8.9
|
L
 -5.9%
H
8.7
9.5
|
L
 -6.9%
H
8.7
10.7
|
L
 -8.7%
H
8.7
10.7
|
L
 -3.1%
H
8.0
11.7
|
L
 -34.6%
H
5.2
16.7
|
L
 71.2%
H
2.2
31.0
|
L
H
2.1
63.8
|
L
H
2.1
63.8
|
Imunon Inc |
|
14.9
|
5.9
|
L
 1.7%
H
5.7
6.0
|
L
 -0.2%
H
5.5
6.0
|
L
 -17.6%
H
5.5
7.2
|
L
 -73.0%
H
5.5
31.8
|
L
 -62.1%
H
5.5
47.4
|
L
 -81.6%
H
5.5
54.8
|
L
 -96.8%
H
5.5
783
|
L
 -99.9%
H
5.5
7276.5
|
Immatics NV |
|
700.2
|
5.8
|
L
 -0.9%
H
5.7
5.8
|
L
 13.2%
H
5.1
6.3
|
L
 -6.8%
H
5.1
6.5
|
L
 -3.5%
H
5.1
6.8
|
L
 -50.9%
H
3.3
13.1
|
L
 -55.9%
H
3.3
13.8
|
L
 -34.0%
H
3.3
18.4
|
L
H
3.3
18.4
|
Immunovant Inc |
|
2,876.2
|
16.5
|
L
 0.8%
H
16.3
16.6
|
L
 12.3%
H
14.8
17.4
|
L
 6.7%
H
14.3
17.4
|
L
 -1.6%
H
14.3
19.1
|
L
 -51.5%
H
12.7
34.2
|
L
 224.8%
H
4.3
45.6
|
L
 -53.0%
H
3.1
53.8
|
L
H
3.1
53.8
|
IN8bio Inc |
|
9.2
|
2.0
|
L
 -6.5%
H
2.0
2.2
|
L
 -8.6%
H
2.0
2.3
|
L
 -12.6%
H
2.0
2.5
|
L
 -51.6%
H
2.0
3.7
|
L
 573.3%
H
0.1
4.2
|
L
 -16.9%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
Inhibrx Inc |
|
1,400.5
|
29.6
|
L
 1.6%
H
28.5
30.2
|
L
 4.8%
H
27.0
30.2
|
L
 40.4%
H
20.6
30.2
|
L
 112.4%
H
13.3
30.2
|
L
 96.3%
H
10.8
30.2
|
L
 86.6%
H
10.8
39.8
|
L
 50.1%
H
7.7
51.0
|
L
H
7.7
51.0
|
MiNK Therapeutics Inc |
|
70.5
|
15.6
|
L
 -1.5%
H
15.0
15.9
|
L
 9.5%
H
13.1
16.2
|
L
 29.3%
H
11.7
18.2
|
L
 114.7%
H
6.8
76
|
L
 97.8%
H
0.9
76
|
L
 -46.6%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
INmune Bio Inc |
|
47.1
|
1.8
|
L
 -2.2%
H
1.7
1.8
|
L
 -12.8%
H
1.7
2.1
|
L
 -30.9%
H
1.7
2.6
|
L
 -76.8%
H
1.7
11.6
|
L
 -69.9%
H
1.7
11.6
|
L
 -78.3%
H
1.7
14.7
|
L
 -81.0%
H
1.7
30.4
|
L
H
1.7
30.4
|
IO Biotech Inc |
|
119.2
|
1.8
|
L
 0.6%
H
1.7
1.8
|
L
 14.6%
H
1.6
2
|
L
H
1.0
2.8
|
L
 13.1%
H
1.0
2.8
|
L
 115.5%
H
0.7
2.8
|
L
 -44.8%
H
0.7
3.5
|
L
H
0.7
17.9
|
L
H
0.7
17.9
|
Iovance Biotherapeutics Inc |
|
854.0
|
2.4
|
L
 -0.8%
H
2.3
2.4
|
L
 5.8%
H
2.1
2.5
|
L
 11.9%
H
2.0
2.8
|
L
 15.1%
H
1.7
4.3
|
L
 -76.4%
H
1.6
12.5
|
L
 -79.1%
H
1.6
18.3
|
L
 -92.5%
H
1.6
54.2
|
L
 -68.0%
H
1.6
54.2
|
Century Therapeutics Inc |
|
43.2
|
0.5
|
L
 -2.0%
H
0.5
0.5
|
L
 2.0%
H
0.5
0.5
|
L
 -2.0%
H
0.5
0.6
|
L
 -19.4%
H
0.5
0.7
|
L
 -65.8%
H
0.3
1.9
|
L
 -95.5%
H
0.3
12.0
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
Disc Medicine Inc |
|
2,173.5
|
62.5
|
L
 1.0%
H
62.3
65.3
|
L
 4.8%
H
58.9
65.3
|
L
 7.7%
H
57.0
65.3
|
L
 25.0%
H
48.9
65.3
|
L
 24.2%
H
30.8
68.7
|
L
 328.2%
H
11.8
77.6
|
L
 -40.2%
H
11.6
190.9
|
L
H
11.6
190.9
|
Invivyd Inc |
|
240.8
|
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 18.6%
H
1.0
1.2
|
L
 43.8%
H
0.5
1.2
|
L
 16.2%
H
0.5
1.2
|
L
 42.0%
H
0.4
2.7
|
L
 -75.2%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
Immunocore Holdings plc ADR |
|
1,836.6
|
36.5
|
L
 -0.5%
H
35.3
36.9
|
L
 13.1%
H
31.9
38.2
|
L
 14.0%
H
31.0
38.2
|
L
 -2.2%
H
30.8
38.2
|
L
 9.1%
H
23.2
39.3
|
L
 -36.5%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
Immutep ADR |
|
243.7
|
1.7
|
L
 -3.5%
H
1.6
1.7
|
L
 3.1%
H
1.6
1.8
|
L
 -7.3%
H
1.6
1.9
|
L
 -10.8%
H
1.5
1.9
|
L
 -34.7%
H
1.3
2.7
|
L
 -9.8%
H
1.3
3.9
|
L
 19.4%
H
1.3
8.0
|
L
 -64.7%
H
0.5
8.0
|
Inventiva ADR |
|
738.4
|
5.3
|
L
 -1.1%
H
5.3
5.5
|
L
 -14.2%
H
5.2
6.1
|
L
 48.3%
H
3.4
6.5
|
L
 47.5%
H
2.9
6.5
|
L
 141.4%
H
1.5
6.5
|
L
 32.4%
H
1.5
11.8
|
L
 -54.0%
H
1.5
19.1
|
L
H
1.5
19.1
|
Janux Therapeutics Inc |
|
1,462.1
|
24.3
|
L
 -1.9%
H
24.2
25.0
|
L
 7.1%
H
22.4
25.6
|
L
 6.6%
H
22.0
26.1
|
L
 -7.2%
H
22.0
28.4
|
L
 -41.0%
H
22.0
71.7
|
L
 82.1%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
Jasper Therapeutics Inc |
|
41.4
|
2.6
|
L
 -3.8%
H
2.5
2.7
|
L
 -8.9%
H
2.5
2.9
|
L
 4.1%
H
2.5
3.1
|
L
 -57.6%
H
2.3
7.2
|
L
 -86.3%
H
2.3
26.1
|
L
 30.1%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
Kamada Ltd |
|
410.6
|
7.1
|
L
 -1.1%
H
7.1
7.2
|
L
 3.2%
H
6.9
7.4
|
L
 0.3%
H
6.9
7.9
|
L
 4.2%
H
6.8
8.2
|
L
 33.5%
H
5.2
9.2
|
L
 45.1%
H
3.7
9.2
|
L
 -22.2%
H
3.7
9.6
|
L
 101.7%
H
3.2
13.3
|
Kodiak Sciences Inc |
|
506.6
|
9.6
|
L
 -2.0%
H
9.4
9.8
|
L
 6.1%
H
8.3
10.6
|
L
 21.4%
H
7.8
11.3
|
L
 127.3%
H
3.4
11.3
|
L
 315.2%
H
1.9
11.6
|
L
 -2.8%
H
1.4
11.6
|
L
 -79.8%
H
1.4
171.2
|
L
H
1.4
171.2
|
Krystal Biotech Inc |
|
4,112.2
|
142.1
|
L
 -2.2%
H
140.9
146.1
|
L
 -3.8%
H
140.9
153.0
|
L
 2.5%
H
137.4
153.0
|
L
 3.8%
H
128.0
159
|
L
 -22.9%
H
122.8
207.8
|
L
 99.4%
H
61.1
219.3
|
L
 226.6%
H
38.9
219.3
|
L
H
8.0
219.3
|
TuHURA Biosciences Inc. |
|
115.1
|
2.3
|
L
 -8.7%
H
2.3
2.5
|
L
 -14.8%
H
2.3
2.8
|
L
H
2.3
3.9
|
L
 -18.2%
H
2.1
3.9
|
L
 -62.2%
H
0.2
8.4
|
L
 -99.1%
H
0.2
542.5
|
L
 -99.9%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
Kura Oncology Inc |
|
690.0
|
8.0
|
L
 -2.3%
H
7.9
8.2
|
L
 0.6%
H
7.9
8.9
|
L
 43.5%
H
5.5
8.9
|
L
 18.1%
H
5.5
8.9
|
L
 -58.8%
H
5.4
21.4
|
L
 -46.8%
H
5.4
24.2
|
L
 -68.9%
H
5.4
43
|
L
H
2.5
43
|
Kymera Therapeutics Inc |
|
3,150.2
|
44.1
|
L
 1.9%
H
43.1
44.4
|
L
 6.9%
H
39.8
44.4
|
L
 8.5%
H
36.7
44.5
|
L
 -7.5%
H
36.7
50.3
|
L
 -3.0%
H
19.4
53.3
|
L
 53.1%
H
9.6
53.3
|
L
 61.5%
H
9.6
91.9
|
L
H
9.6
91.9
|
Kezar Life Sciences Inc |
|
29.2
|
4.0
|
L
 -0.5%
H
4.0
4.0
|
L
 1.0%
H
3.8
4.1
|
L
 -0.3%
H
3.8
4.2
|
L
 -9.3%
H
3.8
5
|
L
 -28.8%
H
0.7
9.2
|
L
 -95.8%
H
0.7
105.1
|
L
 -91.5%
H
0.7
185.5
|
L
H
0.7
363.3
|
Longeveron Inc - Ordinary ... |
|
17.1
|
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 -1.2%
H
0.7
0.9
|
L
 20.6%
H
0.7
0.9
|
L
 -33.3%
H
0.6
1.8
|
L
 -58.4%
H
0.6
2.5
|
L
 -98.3%
H
0.6
52.2
|
L
H
0.6
450
|
L
H
0.6
450
|
Lixte Biotechnology Holdin... |
|
22.1
|
4.9
|
L
 12.3%
H
4.3
4.9
|
L
 9.0%
H
4.0
4.9
|
L
 0.4%
H
3.1
5.1
|
L
 264.7%
H
0.6
5.1
|
L
 148.7%
H
0.6
5.1
|
L
 -34.4%
H
0.6
27
|
L
 -93.3%
H
0.6
78.6
|
L
 -68.9%
H
0.6
110.4
|
Leap Therapeutics Inc |
|
11.2
|
0.3
|
L
 -6.9%
H
0.3
0.3
|
L
 -6.9%
H
0.3
0.3
|
L
 -15.6%
H
0.2
0.4
|
L
 -30.8%
H
0.2
0.5
|
L
 -90.4%
H
0.2
4.8
|
L
 -98.3%
H
0.2
17.5
|
L
 -98.7%
H
0.2
41.7
|
L
H
0.2
102.5
|
Larimar Therapeutics Inc |
|
328.7
|
3.8
|
L
 -2.3%
H
3.8
4.0
|
L
 6.1%
H
3.7
4.1
|
L
 7.3%
H
3.5
4.4
|
L
 43.3%
H
2.2
4.4
|
L
 -52.3%
H
1.6
9.5
|
L
 25.9%
H
1.6
13.7
|
L
 -71.9%
H
1.5
25.9
|
L
 -99.2%
H
1.5
575.8
|
LAVA Therapeutics NV |
|
41.0
|
1.6
|
L
 0.7%
H
1.5
1.6
|
L
 -0.6%
H
1.5
1.6
|
L
 2.0%
H
1.5
1.6
|
L
 18.2%
H
1.3
1.7
|
L
 -2.5%
H
0.9
2.1
|
L
 -39.1%
H
0.9
7.4
|
L
H
0.9
17.2
|
L
H
0.9
17.2
|
Lyell Immunopharma Inc |
|
254.5
|
13.3
|
L
 1.7%
H
12.5
13.3
|
L
 19.6%
H
10.8
13.3
|
L
 20.7%
H
9.3
13.3
|
L
 3.8%
H
8.5
14.2
|
L
 -43.4%
H
7.7
32
|
L
 -91.2%
H
7.7
174.8
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
Microbot Medical Inc |
|
192.1
|
4.0
|
L
 -12%
H
4.0
4.4
|
L
 3.9%
H
3.2
4.7
|
L
 28.2%
H
2.9
4.7
|
L
 40.9%
H
2.3
4.7
|
L
 350%
H
0.9
4.7
|
L
 -24.3%
H
0.8
6.1
|
L
 -40%
H
0.8
10.7
|
L
 -99.6%
H
0.8
1020.6
|
Seres Therapeutics Inc |
|
164.8
|
18.8
|
L
 -17.6%
H
18.5
24.0
|
L
 -0.6%
H
17.8
24.7
|
L
 32.4%
H
14.1
24.7
|
L
 128.7%
H
7.2
24.7
|
L
 1881.1%
H
0.4
24.7
|
L
 180.5%
H
0.4
24.7
|
L
 -19.6%
H
0.4
38.5
|
L
 -61.0%
H
0.4
52
|
MeiraGTx Holdings plc |
|
597.7
|
7.4
|
L
 -0.5%
H
7.3
7.5
|
L
 1.8%
H
7.2
8.1
|
L
 -5.7%
H
7.2
8.6
|
L
 23.8%
H
6.0
9.0
|
L
 91.5%
H
3.9
9.0
|
L
 -20.4%
H
3.5
9.5
|
L
 -42.9%
H
3.5
24.9
|
L
H
3.5
30.2
|
Mineralys Therapeutics Inc |
|
2,828.6
|
37.2
|
L
 3.5%
H
35.9
37.4
|
L
 140.1%
H
22
37.4
|
L
 185.9%
H
12.6
37.4
|
L
 130.6%
H
12.6
37.4
|
L
 231.0%
H
8.2
37.4
|
L
H
5.9
37.4
|
L
H
5.9
37.4
|
L
H
5.9
37.4
|
Monopar Therapeutics Inc |
|
274.3
|
44.5
|
L
 7.2%
H
41.7
44.6
|
L
 30.2%
H
32.8
44.6
|
L
 28.3%
H
29.2
44.6
|
L
 19.8%
H
29.2
50.1
|
L
 1759.8%
H
2.3
54.1
|
L
 419.9%
H
1.4
54.1
|
L
 61.1%
H
1.4
85.1
|
L
H
1.4
240
|
Marker Therapeutics Inc |
|
10.9
|
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 -9.7%
H
0.8
0.9
|
L
 -29.4%
H
0.8
1.3
|
L
 -52.5%
H
0.8
4.1
|
L
 -71.8%
H
0.8
6.0
|
L
 -79%
H
0.7
9.7
|
L
 -94.7%
H
0.7
37.7
|
L
 -98.4%
H
0.7
135.5
|
Moderna |
|
9,583.0
|
24.6
|
L
 -0.8%
H
24.3
25.5
|
L
 2.2%
H
23.3
25.5
|
L
 -5.7%
H
23.3
28.6
|
L
 -10.3%
H
23.3
35.6
|
L
 -66.2%
H
23.2
80.0
|
L
 -82.6%
H
23.2
217.3
|
L
 -54.7%
H
23.2
497.5
|
L
H
11.5
497.5
|
Mersana Therapeutics Inc |
|
35.2
|
7.1
|
L
 0.3%
H
6.9
7.2
|
L
 -3.6%
H
6.6
7.6
|
L
 12.1%
H
5.2
8.2
|
L
 -26.8%
H
5.2
11.5
|
L
 -79.1%
H
5.2
70.8
|
L
 -96.5%
H
5.2
240.5
|
L
 -98.4%
H
5.2
727.3
|
L
H
5.2
727.3
|
Merus N.V |
|
5,081.1
|
67.2
|
L
 0.0%
H
65.7
68.7
|
L
 2.0%
H
62.8
68.7
|
L
 5.0%
H
62.2
69.2
|
L
 19.5%
H
51.8
69.2
|
L
 34.4%
H
33.2
69.2
|
L
 183.7%
H
12.0
69.2
|
L
 535.6%
H
10.6
69.2
|
L
H
7.3
69.2
|
Maravai LifeSciences Holdi... |
|
368.9
|
2.6
|
L
 4.5%
H
2.4
2.6
|
L
 5.4%
H
2.3
2.6
|
L
 15.9%
H
2.0
2.8
|
L
 6.7%
H
2.0
2.9
|
L
 -71.8%
H
1.7
9.5
|
L
 -88.5%
H
1.7
26.6
|
L
H
1.7
63.6
|
L
H
1.7
63.6
|
MaxCyte Inc |
|
152.4
|
1.4
|
L
 1.4%
H
1.4
1.5
|
L
 2.9%
H
1.3
1.5
|
L
 3.6%
H
1.3
1.5
|
L
 -33.5%
H
1.3
2.4
|
L
 -62.3%
H
1.3
5.2
|
L
 -77.9%
H
1.3
7.5
|
L
 -12.3%
H
1.3
17.4
|
L
H
1.3
17.4
|
Mainz Biomed N.V. |
|
7.6
|
1.7
|
L
 1.8%
H
1.6
1.7
|
L
 -0.6%
H
1.6
1.8
|
L
 16.8%
H
1.4
1.9
|
L
 -19.7%
H
1.3
2.3
|
L
 -87.2%
H
1.3
16.0
|
L
 -99.5%
H
1.3
384.5
|
L
H
1.3
1200
|
L
H
1.3
1200
|
Mesoblast Ltd - ADR |
|
1,903.8
|
14.9
|
L
 2.1%
H
14.6
14.9
|
L
 7.5%
H
12.7
15
|
L
 -1.1%
H
12.7
16.4
|
L
 26.0%
H
9.9
17.6
|
L
 143.6%
H
6
22
|
L
 403.7%
H
1.0
22
|
L
 -9.2%
H
1.0
22
|
L
 27.8%
H
1.0
22
|
Molecular Partners AG - ADR |
|
139.1
|
3.7
|
L
 3.9%
H
3.7
3.7
|
L
 -0.8%
H
3.5
3.9
|
L
 1.6%
H
3.5
4.8
|
L
 -2.1%
H
3.4
4.8
|
L
 -32.5%
H
3.4
7.6
|
L
 -35.1%
H
3.3
12.7
|
L
 -77.6%
H
3.3
32.0
|
L
 -89.1%
H
3.3
38.8
|
Mereo Biopharma Group Plc ... |
|
283.0
|
1.8
|
L
 -0.6%
H
1.8
1.8
|
L
 4.1%
H
1.7
1.8
|
L
 16.3%
H
1.5
1.8
|
L
 -35.0%
H
1.5
3.1
|
L
 -58.8%
H
1.5
4.7
|
L
 76.2%
H
0.5
5.0
|
L
 -33.3%
H
0.3
5.0
|
L
H
0.3
8.5
|
Nautilus Biotechnology Inc |
|
84.6
|
0.7
|
L
 -4.3%
H
0.7
0.7
|
L
 -1.5%
H
0.6
0.7
|
L
 -8.2%
H
0.6
0.8
|
L
 -13.0%
H
0.6
0.9
|
L
 -73.7%
H
0.6
3.1
|
L
 -69.3%
H
0.6
4.7
|
L
 -93.8%
H
0.6
25.9
|
L
H
0.6
25.9
|
Nkarta Inc |
|
146.3
|
2.1
|
L
 -2.8%
H
2.0
2.1
|
L
 -2.8%
H
2.0
2.3
|
L
 4.0%
H
2.0
2.5
|
L
 8.4%
H
1.6
2.5
|
L
 -61.3%
H
1.3
6.6
|
L
 -86.3%
H
1.3
16.2
|
L
 -92.1%
H
1.3
79.2
|
L
H
1.3
79.2
|
Neoleukin Therapeutics Inc |
|
-
|
19.5
|
L
 -2.5%
H
18.8
20.0
|
L
 5.3%
H
18.4
20.7
|
L
 -8.3%
H
18
21.7
|
L
 -10.9%
H
14.7
23.9
|
L
 8.1%
H
14.7
25.2
|
L
 -5.6%
H
7.5
25.2
|
L
 -92.1%
H
7.5
359
|
L
 -93.8%
H
7.5
447.6
|
9 Meters Biopharma Inc |
|
-
|
7.3
|
L
 -1.5%
H
7.3
7.4
|
L
 1.1%
H
6.9
7.5
|
L
 9.9%
H
6.6
7.5
|
L
 7.8%
H
6.2
7.5
|
L
 2.5%
H
6.2
7.5
|
L
 38.5%
H
0.0
7.5
|
L
 -40.9%
H
0.0
45.2
|
L
H
0.0
1010
|
MetaVia Inc. |
|
16.5
|
0.7
|
L
 -1.5%
H
0.7
0.7
|
L
 7.9%
H
0.6
0.7
|
L
 7.9%
H
0.6
0.7
|
L
 -1.5%
H
0.6
0.8
|
L
 -80.6%
H
0.6
4.3
|
L
 -92.4%
H
0.4
63.9
|
L
 -99.6%
H
0.4
228.3
|
L
H
0.4
16192.5
|
Intellia Therapeutics Inc |
|
1,222.7
|
11.4
|
L
 -3.8%
H
11.3
12.0
|
L
 0.3%
H
11.1
12.5
|
L
 5.6%
H
9.8
12.5
|
L
 40.8%
H
8
14.6
|
L
 -42.2%
H
5.9
23.8
|
L
 -81.4%
H
5.9
69.3
|
L
 -34.8%
H
5.9
202.7
|
L
H
5.9
202.7
|
Nuvalent Inc - Ordinary Sh... |
|
5,609.8
|
77.8
|
L
 -2.5%
H
77.3
79.9
|
L
 1.6%
H
74.4
82.8
|
L
 5.0%
H
71.7
82.8
|
L
 -0.3%
H
71.1
86.8
|
L
 -9.8%
H
55.5
113.5
|
L
 353.4%
H
15.6
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
Novavax, Inc. |
|
1,288.0
|
7.9
|
L
 2.6%
H
7.7
8.0
|
L
 6.2%
H
7.2
8.0
|
L
 -5.3%
H
7.2
10.6
|
L
 6.4%
H
6.1
10.6
|
L
 -31.8%
H
5.0
15.2
|
L
 -73.8%
H
3.5
33.4
|
L
 -90.7%
H
3.5
331.7
|
L
 -96.3%
H
3.5
331.7
|
NuCana plc - ADR |
|
5.5
|
2.9
|
L
 0.4%
H
2.9
3.0
|
L
 -9.1%
H
2.8
3.2
|
L
 -55.0%
H
2.8
5.7
|
L
 -99.9%
H
2.8
8000
|
L
 -100%
H
2.8
330000
|
L
 -100.0%
H
2.8
1750000
|
L
 -100.0%
H
2.8
7830000
|
L
H
2.8
32000000
|
Insight Molecular Diagnost... |
|
70.4
|
2.5
|
L
 -1.2%
H
2.4
2.6
|
L
 -2.8%
H
2.4
2.6
|
L
 -4.3%
H
2.3
2.9
|
L
 -17.2%
H
2.3
4.2
|
L
 -22.9%
H
1.9
4.8
|
L
 -84.5%
H
1.9
19.3
|
L
 -91.3%
H
1.9
131.4
|
L
H
1.9
204.8
|
OKYO Pharma Limited - Ordi... |
|
82.7
|
2.2
|
L
 -0.5%
H
2.2
2.2
|
L
 -6.4%
H
2.2
2.4
|
L
 -32.7%
H
2.1
3.3
|
L
 15.8%
H
1.9
3.4
|
L
 115.7%
H
0.9
3.4
|
L
 -30.6%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
Oncolytics Biotech, Inc. |
|
139.7
|
1.4
|
L
 7.8%
H
1.3
1.4
|
L
 32.7%
H
1.0
1.4
|
L
 60.5%
H
0.8
1.4
|
L
 283.3%
H
0.4
1.4
|
L
 43.8%
H
0.3
1.5
|
L
 -1.4%
H
0.3
3.4
|
L
 -14.8%
H
0.3
4.8
|
L
 -75%
H
0.3
8.5
|
Traws Pharma Inc. |
|
13.4
|
1.9
|
L
 2.2%
H
1.7
1.9
|
L
 35.7%
H
1.3
1.9
|
L
 26.7%
H
1.3
2.0
|
L
 15.2%
H
1.3
2.0
|
L
 -79.0%
H
1.0
19.4
|
L
 -93.4%
H
1.0
37.3
|
L
 -97.6%
H
1.0
723.8
|
L
 -100.0%
H
1.0
106312.5
|
VivoSim Labs Inc. |
|
7.4
|
2.8
|
L
 14.1%
H
2.4
2.9
|
L
 16.4%
H
2.1
3.1
|
L
 63.2%
H
1.7
3.1
|
L
 54.4%
H
1.4
3.1
|
L
 -56.3%
H
0.3
22.0
|
L
 -90.1%
H
0.3
40.8
|
L
 -96.4%
H
0.3
287.0
|
L
 -99.6%
H
0.3
1197.6
|
Passage Bio Inc |
|
22.0
|
6.9
|
L
 -0.1%
H
6.8
7.3
|
L
 -3.1%
H
6.7
7.6
|
L
 10.2%
H
5.5
7.8
|
L
 -18.3%
H
5.1
9.8
|
L
 -50.9%
H
5.1
26.6
|
L
 -81.2%
H
5.1
40
|
L
 -97.8%
H
5.1
617.4
|
L
H
5.1
764.6
|
Vaxcyte Inc |
|
4,166.0
|
32.1
|
L
 -1.0%
H
31.7
32.7
|
L
 4.2%
H
30.9
33.7
|
L
 7.3%
H
29.5
33.7
|
L
 -13.3%
H
29.1
38.4
|
L
 -71.2%
H
27.7
121.1
|
L
 13.6%
H
20.5
121.1
|
L
 -10.7%
H
15.5
121.1
|
L
H
15.5
121.1
|
PepGen Inc |
|
49.2
|
1.5
|
L
 0.7%
H
1.5
1.9
|
L
 29.3%
H
1.2
1.9
|
L
 40.2%
H
1.0
1.9
|
L
H
1.0
1.9
|
L
 -83.0%
H
0.9
10.1
|
L
 -86.0%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
Precigen Inc |
|
1,212.7
|
4.1
|
L
 -2.2%
H
4.0
4.3
|
L
 -9.8%
H
4.0
5.2
|
L
 128.7%
H
1.7
5.2
|
L
 171.3%
H
1.4
5.2
|
L
 333.0%
H
0.7
5.2
|
L
 65.4%
H
0.7
5.2
|
L
 -15.7%
H
0.7
11.1
|
L
 -90.7%
H
0.7
53.4
|
Phio Pharmaceuticals Corp |
|
13.2
|
2.3
|
L
 9.0%
H
2.1
2.3
|
L
 17.3%
H
2.0
2.3
|
L
 2.7%
H
1.9
2.3
|
L
 -22.0%
H
1.9
3.5
|
L
 -11.5%
H
1.0
9.8
|
L
 -97.0%
H
0.6
110.4
|
L
 -98.9%
H
0.6
470.9
|
L
 -100.0%
H
0.6
385743.6
|
Pliant Therapeutics Inc |
|
103.1
|
1.7
|
L
 -2.9%
H
1.7
1.8
|
L
 2.4%
H
1.6
1.9
|
L
 1.2%
H
1.4
1.9
|
L
 3.1%
H
1.1
1.9
|
L
 -87.0%
H
1.1
16.1
|
L
 -91.8%
H
1.1
36.6
|
L
 -93.1%
H
1.1
43.9
|
L
H
1.1
43.9
|
Pluri Inc |
|
37.4
|
4.8
|
L
 0.4%
H
4.5
4.8
|
L
 -9.9%
H
4.5
5.3
|
L
 -1.5%
H
4.4
5.7
|
L
H
3.9
6.0
|
L
 -12.8%
H
3.3
7.1
|
L
 -36.2%
H
0.7
11.6
|
L
 -94.0%
H
0.7
94.8
|
L
 -96.9%
H
0.7
174.4
|
Prelude Therapeutics Inc |
|
67.4
|
1.2
|
L
 -4.8%
H
1.2
1.2
|
L
 -1.7%
H
1.1
1.3
|
L
 38.4%
H
0.8
1.3
|
L
 15.5%
H
0.8
1.3
|
L
 -75.5%
H
0.6
5.5
|
L
 -85.0%
H
0.6
8.7
|
L
H
0.6
95.4
|
L
H
0.6
95.4
|
Prime Medicine Inc |
|
704.2
|
4.0
|
L
 1.5%
H
3.8
4.0
|
L
 21.9%
H
3.1
4
|
L
 4.5%
H
3.1
4
|
L
 133.7%
H
1.4
5.2
|
L
 11.3%
H
1.1
5.2
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
ProKidney Corp - Ordinary ... |
|
292.9
|
2.2
|
L
 0.5%
H
2.1
2.2
|
L
 -8.1%
H
2.1
2.4
|
L
 -16.2%
H
2.1
2.6
|
L
 121.4%
H
0.5
7.1
|
L
 -6.9%
H
0.5
7.1
|
L
 -73.4%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
Prothena Corporation plc |
|
440.3
|
8.2
|
L
 -3.7%
H
8.1
8.5
|
L
 -0.2%
H
8.1
8.6
|
L
 6.4%
H
7.4
9.0
|
L
 51.2%
H
5.0
9.0
|
L
 -59.8%
H
4.3
22.7
|
L
 -71.9%
H
4.3
79.7
|
L
 -33.5%
H
4.3
79.8
|
L
 -85.5%
H
4.3
79.8
|
AlphaTON Capital Corp |
|
13.4
|
5.9
|
L
 0.2%
H
5.2
6.7
|
L
 -18.1%
H
5.0
9.4
|
L
 -36.6%
H
5.0
9.7
|
L
 -29.9%
H
5.0
10.3
|
L
 98.7%
H
2.8
23.0
|
L
 -96.6%
H
2.1
179
|
L
 -97.2%
H
2.1
899.5
|
L
 -98.6%
H
0.2
1310
|
Protagonist Therapeutics Inc |
|
3,667.4
|
59.0
|
L
 4.9%
H
54.5
59.3
|
L
 -0.2%
H
54.5
61.0
|
L
 15.4%
H
50.6
61.9
|
L
 8.4%
H
49.4
61.9
|
L
 42.1%
H
33.3
61.9
|
L
 546.4%
H
7.2
61.9
|
L
 187.4%
H
6.9
61.9
|
L
H
4.5
61.9
|
PureTech Health Plc - ADR |
|
386.7
|
16
|
L
 -2.6%
H
15.9
16
|
L
 -6.3%
H
15.8
16.8
|
L
 -7.3%
H
15.2
19.8
|
L
 -15.8%
H
15.2
19.8
|
L
 -21.4%
H
13.3
25.0
|
L
 -45.8%
H
13.3
38.9
|
L
H
13.3
65.9
|
L
H
13.3
65.9
|
Quince Therapeutics Inc |
|
84.3
|
1.6
|
L
H
1.6
1.6
|
L
 -1.9%
H
1.5
1.7
|
L
 -4.9%
H
1.5
1.9
|
L
 34.2%
H
1.2
2.1
|
L
 124.3%
H
0.7
2.5
|
L
 -4.8%
H
0.5
2.5
|
L
 -96.5%
H
0.5
122.0
|
L
H
0.5
122.0
|
uniQure N.V. |
|
947.6
|
17.3
|
L
 -0.9%
H
17.1
17.8
|
L
 5.8%
H
16.1
18.2
|
L
 30.1%
H
12.9
18.2
|
L
H
12.3
18.2
|
L
 218.6%
H
4.5
19
|
L
 -17.4%
H
3.7
28.3
|
L
 -56.9%
H
3.7
52.2
|
L
 -36.4%
H
3.7
82.5
|
Rain Oncology Inc |
|
192.8
|
5.3
|
L
 -13.3%
H
5
5.6
|
L
 37.7%
H
3.9
6.5
|
L
 61.1%
H
3.1
6.5
|
L
 43.6%
H
2.7
6.5
|
L
 338.0%
H
1.4
9.2
|
L
 -8.1%
H
0.8
14.5
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
Rani Therapeutics Holdings... |
|
23.9
|
0.5
|
L
H
0.5
0.5
|
L
 -2.0%
H
0.4
0.5
|
L
 -5.7%
H
0.4
0.6
|
L
 -10.7%
H
0.4
0.9
|
L
 -80.9%
H
0.4
3.8
|
L
 -94.8%
H
0.4
10.8
|
L
 -99.8%
H
0.4
36.3
|
L
H
0.4
224.5
|
Rocket Pharmaceuticals Inc |
|
341.0
|
3.2
|
L
 -3.1%
H
3.1
3.3
|
L
 -3.7%
H
3.1
3.4
|
L
 10.5%
H
2.8
4.1
|
L
 3.3%
H
2.4
4.1
|
L
 -82.9%
H
2.2
22.0
|
L
 -79.9%
H
2.2
32.5
|
L
 -86.3%
H
2.2
67.5
|
L
 -94.1%
H
2.2
67.5
|
Replimune Group Inc |
|
451.2
|
5.8
|
L
 -4.3%
H
5.8
6.2
|
L
 7.0%
H
5.5
6.5
|
L
 9.3%
H
4.5
6.5
|
L
 -44.3%
H
2.7
13.2
|
L
 -44.3%
H
2.7
17
|
L
 -68.4%
H
2.7
29.5
|
L
 -76.2%
H
2.7
54.9
|
L
H
2.7
54.9
|
Revelation Biosciences Inc |
|
4.0
|
2.4
|
L
 -16.3%
H
2.2
2.5
|
L
 -14.5%
H
2.2
2.9
|
L
 -0.8%
H
2.2
2.9
|
L
 -8.5%
H
2.1
3.2
|
L
 -94.4%
H
0.7
60.5
|
L
 -100.0%
H
0.7
25270.6
|
L
H
0.7
569016
|
L
H
0.7
569016
|
Relay Therapeutics Inc |
|
700.0
|
4.1
|
L
H
4.0
4.1
|
L
 13.1%
H
3.6
4.3
|
L
 26.1%
H
3.2
4.3
|
L
 20.8%
H
3.0
4.3
|
L
 -34.9%
H
1.8
10.7
|
L
 -87.1%
H
1.8
31.6
|
L
 -88.5%
H
1.8
64.4
|
L
H
1.8
64.4
|
Avidity Biosciences Inc |
|
5,992.7
|
46.6
|
L
 -3.1%
H
46.4
48.0
|
L
H
45.2
51.4
|
L
 0.6%
H
42.7
51.4
|
L
 28.5%
H
27.7
51.4
|
L
 15.1%
H
21.5
56
|
L
 106.1%
H
4.8
56
|
L
 53.5%
H
4.8
56
|
L
H
4.8
56
|
TransCode Therapeutics Inc |
|
9.1
|
10.9
|
L
 0.6%
H
10.9
11.5
|
L
 12.2%
H
9.5
11.5
|
L
 5.1%
H
9.3
11.8
|
L
 52.9%
H
6.8
17.2
|
L
 -95.5%
H
6.2
739.2
|
L
 -100.0%
H
6.2
1145760
|
L
H
6.2
5174400
|
L
H
6.2
5174400
|
Recursion Pharmaceuticals ... |
|
2,030.0
|
4.7
|
L
 0.7%
H
4.6
4.7
|
L
 -1.1%
H
4.5
4.8
|
L
 -13.3%
H
4.5
5.8
|
L
 -15.3%
H
4.5
7.2
|
L
 -21.5%
H
3.8
12.4
|
L
 -63.8%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
Rhythm Pharmaceuticals Inc. |
|
6,657.9
|
100.2
|
L
 0.5%
H
97.5
100.7
|
L
 -2.8%
H
97.5
106.5
|
L
 9.0%
H
89.2
106.5
|
L
 47.2%
H
60.7
106.5
|
L
 103.5%
H
45.9
106.5
|
L
 320.1%
H
15.5
106.5
|
L
 241.0%
H
3.0
106.5
|
L
H
3.0
106.5
|
SAB Biotherapeutics Inc |
|
21.9
|
2.1
|
L
H
2.1
2.2
|
L
 1.0%
H
2.1
2.3
|
L
 -4.6%
H
1.9
2.3
|
L
 16.0%
H
1.6
6.6
|
L
 -26.1%
H
1
6.6
|
L
 218.2%
H
0.4
6.6
|
L
H
0.4
12.9
|
L
H
0.4
12.9
|
Sana Biotechnology Inc |
|
756.6
|
3.0
|
L
 -0.7%
H
2.9
3.0
|
L
 -2.6%
H
2.8
3.1
|
L
 -0.7%
H
2.8
3.8
|
L
 4.9%
H
2.4
5.3
|
L
 -40.9%
H
1.3
7.3
|
L
 -59.3%
H
1.3
12
|
L
H
1.3
44.6
|
L
H
1.3
44.6
|
Cassava Sciences Inc |
|
103.9
|
2.2
|
L
 0.5%
H
2.1
2.2
|
L
 -5.7%
H
2.1
2.4
|
L
 -1.4%
H
2.1
2.4
|
L
 -1.8%
H
1.8
2.7
|
L
 -92.0%
H
1.2
34.0
|
L
 -92.7%
H
1.2
51.6
|
L
 -30.2%
H
1.2
146.2
|
L
 -83.5%
H
0.8
146.2
|
Seer Inc - Ordinary Shares... |
|
113.8
|
2.0
|
L
 -0.5%
H
2
2.1
|
L
 -1.5%
H
2.0
2.1
|
L
 -12.2%
H
2.0
2.2
|
L
 -11.4%
H
1.9
2.3
|
L
 23.2%
H
1.6
2.6
|
L
 -79.3%
H
1.5
10.3
|
L
H
1.5
86.6
|
L
H
1.5
86.6
|
Selecta Biosciences Inc |
|
1,578.0
|
10.2
|
L
 -4.2%
H
10.2
10.7
|
L
 1.4%
H
9.7
10.8
|
L
 -3.2%
H
9.7
12.3
|
L
 -7.7%
H
9.4
15.6
|
L
 -0.7%
H
8.5
15.6
|
L
 -0.7%
H
8.5
15.6
|
L
 -0.7%
H
8.5
15.6
|
L
 -0.7%
H
8.5
15.6
|
Sangamo Therapeutics Inc |
|
153.9
|
0.5
|
L
 -1.9%
H
0.5
0.5
|
L
 -1.9%
H
0.5
0.6
|
L
 10.9%
H
0.4
0.6
|
L
 -3.8%
H
0.4
0.7
|
L
 -29.2%
H
0.4
3.2
|
L
 -91.2%
H
0.3
5.9
|
L
 -95%
H
0.3
19.4
|
L
 -92.6%
H
0.3
27.5
|
Solid Biosciences Inc |
|
380.0
|
4.9
|
L
 -4.9%
H
4.9
5.1
|
L
 -11.0%
H
4.9
5.8
|
L
 -22.4%
H
4.9
6.8
|
L
 7.5%
H
4.3
7.4
|
L
 -39.8%
H
2.4
8.5
|
L
 -49.0%
H
1.8
15.1
|
L
 -85.2%
H
1.8
173.7
|
L
H
1.8
822.6
|
Summit Therapeutics Inc |
|
13,920.9
|
18.7
|
L
 -3.6%
H
18.7
19.6
|
L
 -20.9%
H
18.7
26.5
|
L
 -34.6%
H
18.7
29.4
|
L
 -9.0%
H
18.7
31.0
|
L
 52.7%
H
15.6
36.9
|
L
 1411.3%
H
0.7
36.9
|
L
 471.3%
H
0.7
36.9
|
L
 64.4%
H
0.7
36.9
|
Syndax Pharmaceuticals Inc |
|
1,364.5
|
15.8
|
L
 -3%
H
15.8
16.3
|
L
 -3%
H
15.8
17.2
|
L
 26.9%
H
12.1
17.2
|
L
 38.3%
H
8.6
17.2
|
L
 -17.1%
H
8.6
22.5
|
L
 -36.1%
H
8.6
29.9
|
L
 5.2%
H
8.6
29.9
|
L
H
3.4
29.9
|
Sensei Biotherapeutics Inc |
|
10.5
|
8.3
|
L
 5.2%
H
8.3
8.3
|
L
 -0.2%
H
7.8
9.2
|
L
 9.0%
H
7.2
9.2
|
L
 21.2%
H
5.6
11.0
|
L
 -31.5%
H
5
17.4
|
L
 -78.5%
H
5
42
|
L
H
5
530
|
L
H
5
530
|
Senti Biosciences Inc. |
|
34.8
|
1.3
|
L
 0.8%
H
1.3
1.3
|
L
 -9.5%
H
1.3
1.5
|
L
 -15.8%
H
1.3
1.7
|
L
 -65.4%
H
1.3
3.8
|
L
 -53.7%
H
1.3
16.9
|
L
 -93.6%
H
1.3
87.7
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
Sonnet BioTherapeutics Hol... |
|
21.4
|
3.1
|
L
 -4.6%
H
3.0
4.4
|
L
 -3.4%
H
2.7
4.4
|
L
 -2.5%
H
2.7
4.4
|
L
 151.2%
H
1.1
19.3
|
L
 -55.0%
H
0.7
19.3
|
L
 -99.4%
H
0.7
739.2
|
L
 -99.9%
H
0.7
8414.6
|
L
 -100.0%
H
0.7
1025024
|
Spero Therapeutics Inc |
|
111.4
|
2.0
|
L
 -1%
H
1.9
2.0
|
L
 -4.4%
H
1.9
2.2
|
L
 -9.6%
H
1.8
2.4
|
L
 -20.8%
H
1.8
3.2
|
L
 50%
H
0.5
3.2
|
L
 62.3%
H
0.5
3.2
|
L
 -84.9%
H
0.5
23.6
|
L
H
0.5
23.6
|
Scholar Rock Holding Corp |
|
3,061.7
|
31.9
|
L
 0.9%
H
31.3
32.1
|
L
 -2.5%
H
31
34.7
|
L
 -0.3%
H
29.6
35.9
|
L
 -7.0%
H
29.6
44.0
|
L
 296.6%
H
6.8
47.0
|
L
 239.6%
H
5.6
47.0
|
L
 124.6%
H
4.3
70
|
L
H
4.3
70
|
Surrozen Inc |
|
97.4
|
11.4
|
L
H
11.4
11.9
|
L
 -6.7%
H
11.4
13.4
|
L
 18.8%
H
9.5
13.4
|
L
 33.7%
H
8
13.4
|
L
 23.1%
H
5.9
18.2
|
L
 330.3%
H
0.3
18.2
|
L
H
0.3
18.2
|
L
H
0.3
18.2
|
Stoke Therapeutics Inc |
|
1,173.8
|
21.4
|
L
 -2.6%
H
20.7
22
|
L
 8.4%
H
18.8
22.4
|
L
 63.5%
H
12.9
22.4
|
L
 92.3%
H
10.9
22.4
|
L
 45.7%
H
5.4
22.4
|
L
 43.3%
H
3.4
22.4
|
L
 -27.3%
H
3.4
71.6
|
L
H
3.4
71.6
|
Shattuck Labs Inc |
|
96.8
|
2.0
|
L
 7.5%
H
1.7
2.0
|
L
 106.1%
H
1.0
2.0
|
L
 165.8%
H
0.7
2.0
|
L
 77.2%
H
0.7
2.0
|
L
 -42.3%
H
0.7
4.0
|
L
 -42.5%
H
0.7
11.8
|
L
H
0.7
60.5
|
L
H
0.7
60.5
|
60 Degrees Pharmaceuticals... |
|
5.7
|
1.4
|
L
 -0.7%
H
1.3
1.4
|
L
 -2.1%
H
1.3
1.5
|
L
 -0.7%
H
1.2
1.5
|
L
 -52.7%
H
1.2
3.1
|
L
 -79.7%
H
1.2
12.5
|
L
H
1.2
519
|
L
H
1.2
519
|
L
H
1.2
519
|
Synlogic Inc |
|
17.1
|
1.5
|
L
 -0.7%
H
1.5
1.5
|
L
 0.7%
H
1.4
1.6
|
L
 4.3%
H
1.4
1.7
|
L
 20.7%
H
1.2
2.0
|
L
 0.7%
H
0.9
2.0
|
L
 -90.6%
H
0.9
20.3
|
L
 -95.3%
H
0.9
76.7
|
L
H
0.9
1156.1
|
Alaunos Therapeutics Inc |
|
5.0
|
2.3
|
L
 3.2%
H
2.2
2.3
|
L
 6.1%
H
2.0
2.4
|
L
 -8.5%
H
1.7
2.9
|
L
 -25.4%
H
1.7
6.2
|
L
 -6.6%
H
1.3
6.2
|
L
 -35.8%
H
0.0
6.2
|
L
 -8.1%
H
0.0
6.2
|
L
 -75.5%
H
0.0
14.9
|
Tscan Therapeutics Inc |
|
105.6
|
1.9
|
L
 -1.1%
H
1.8
1.9
|
L
 3.3%
H
1.7
2.0
|
L
 13.4%
H
1.6
2.0
|
L
 3.3%
H
1.4
2.0
|
L
 -66.5%
H
1.0
6.2
|
L
 -46.9%
H
1.0
9.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
Bio-Techne |
|
8,356.1
|
53.7
|
L
 -0.7%
H
53.5
54.5
|
L
 -1.7%
H
51.6
54.5
|
L
 6.6%
H
49.7
57.4
|
L
 10.3%
H
47.7
60.1
|
L
 -24.9%
H
46.0
81.0
|
L
 -37.3%
H
46.0
90.6
|
L
 -12.5%
H
46.0
136.0
|
L
 127.7%
H
20.0
136.0
|
Terns Pharmaceuticals Inc |
|
646.7
|
7.4
|
L
 1.5%
H
7.3
7.5
|
L
 6.2%
H
6.8
7.8
|
L
 21.6%
H
6.0
7.8
|
L
 99.7%
H
3.5
7.8
|
L
 -5.4%
H
1.9
11.4
|
L
 69.5%
H
1.9
14.0
|
L
H
1.5
28.4
|
L
H
1.5
28.4
|
Instil Bio Inc |
|
175.5
|
26
|
L
 0.9%
H
25.9
28.4
|
L
 -3.7%
H
25.8
33.8
|
L
 -7.1%
H
23.8
33.8
|
L
 -21.0%
H
20.6
42.8
|
L
 82.5%
H
10.8
92
|
L
 320.0%
H
0.3
92
|
L
H
0.3
92
|
L
H
0.3
92
|
Tango Therapeutics Inc |
|
769.9
|
6.9
|
L
 1.6%
H
6.7
7.0
|
L
 3.1%
H
6.3
7.4
|
L
 4.7%
H
6.3
7.4
|
L
 62.4%
H
3.8
7.4
|
L
 -36.5%
H
1.0
10.9
|
L
 86.0%
H
1.0
13.0
|
L
H
1.0
18.8
|
L
H
1.0
18.8
|
Entrada Therapeutics Inc |
|
195.5
|
5.1
|
L
 -2.7%
H
5.1
5.3
|
L
 -6.0%
H
5.1
5.7
|
L
 -1.0%
H
4.9
6.3
|
L
 -38.2%
H
4.9
8.5
|
L
 -65.3%
H
4.9
21.8
|
L
 -65.5%
H
4.9
24.4
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
Trevi Therapeutics Inc |
|
965.7
|
7.9
|
L
 4.3%
H
7.4
8.2
|
L
 9.2%
H
6.9
8.2
|
L
 6.9%
H
6.9
8.8
|
L
 12.3%
H
5.4
8.8
|
L
 168.8%
H
2.4
8.8
|
L
 148.6%
H
1.0
8.8
|
L
 117.3%
H
0.5
8.8
|
L
H
0.5
10.6
|
Taysha Gene Therapies Inc |
|
903.0
|
3.3
|
L
 2.2%
H
3.2
3.3
|
L
 13.4%
H
2.8
3.4
|
L
 21.7%
H
2.7
3.4
|
L
 16.6%
H
2.3
3.4
|
L
 62.3%
H
1.1
3.4
|
L
 7.8%
H
0.5
4.3
|
L
H
0.5
33.4
|
L
H
0.5
33.4
|
Twist Bioscience Corp |
|
1,487.9
|
24.7
|
L
 -6.1%
H
24.3
26.5
|
L
 -8.6%
H
24.3
27.3
|
L
 -3.9%
H
24.3
29.7
|
L
 -21.9%
H
24.3
39.4
|
L
 -32.9%
H
24.3
55.3
|
L
 -41.3%
H
11.5
60.9
|
L
 -60.7%
H
11.5
214.1
|
L
H
11.5
214.1
|
10x Genomics Inc - Ordinar... |
|
1,676.9
|
13.5
|
L
 -3.3%
H
13.3
13.9
|
L
 -3.9%
H
13.0
14.1
|
L
 9.6%
H
12.1
14.6
|
L
 43.0%
H
9.3
14.9
|
L
 -37.5%
H
6.8
24.4
|
L
 -60.4%
H
6.8
63.6
|
L
 -87.6%
H
6.8
209.0
|
L
H
6.8
209.0
|
UroGen Pharma Ltd |
|
951.7
|
20.6
|
L
 -4.0%
H
20.4
21.7
|
L
 5.8%
H
18.2
21.7
|
L
 16.0%
H
17.2
21.7
|
L
 179.1%
H
6.6
21.7
|
L
 55.5%
H
3.4
21.7
|
L
 166.1%
H
3.4
24.1
|
L
 -0.6%
H
3.4
28.2
|
L
H
3.4
69.6
|
Vera Therapeutics Inc - Or... |
|
1,591.1
|
24.9
|
L
 0.7%
H
24.4
25.3
|
L
 15.2%
H
21.6
25.3
|
L
 26.0%
H
19.3
25.3
|
L
 9.8%
H
19.1
25.3
|
L
 -33.0%
H
18.5
51.6
|
L
 21.0%
H
5.2
51.6
|
L
H
5.2
51.6
|
L
H
5.2
51.6
|
Vir Biotechnology Inc |
|
715.4
|
5.2
|
L
 -0.8%
H
5.0
5.2
|
L
 4.3%
H
4.9
5.6
|
L
 19.8%
H
4.2
5.8
|
L
 -5.5%
H
4.2
6.2
|
L
 -33.6%
H
4.2
14.5
|
L
 -76.9%
H
4.2
31.6
|
L
 -82.0%
H
4.2
141.0
|
L
H
4.2
141.0
|
Vor Biopharma Inc |
|
253.4
|
2
|
L
 1.0%
H
2.0
2.0
|
L
 1.5%
H
1.9
2.1
|
L
 -3.4%
H
1.6
2.5
|
L
 809.1%
H
0.2
3.3
|
L
 119.8%
H
0.1
3.3
|
L
 -60.9%
H
0.1
7.6
|
L
H
0.1
63.6
|
L
H
0.1
63.6
|
Verastem Inc |
|
636.4
|
10.3
|
L
 1.1%
H
10.2
10.6
|
L
 11.8%
H
9
11.2
|
L
 53.4%
H
6.8
11.2
|
L
 61.1%
H
4.0
11.2
|
L
 330.8%
H
2.4
11.2
|
L
 -35.2%
H
2.1
16.1
|
L
 -22.4%
H
2.1
59.2
|
L
 -86.1%
H
2.1
124.2
|
VistaGen Therapeutics Inc |
|
111.1
|
3.6
|
L
 4.0%
H
3.5
3.6
|
L
 8.4%
H
3.3
3.9
|
L
 21.9%
H
2.8
3.9
|
L
 53.4%
H
1.9
3.9
|
L
 11.4%
H
1.9
3.9
|
L
 -38.2%
H
1.6
24.7
|
L
 -80.2%
H
1.6
106.5
|
L
 -98.8%
H
1.6
307.5
|
Ventyx Biosciences Inc |
|
171.1
|
2.4
|
L
 0.8%
H
2.3
2.5
|
L
H
2.3
2.7
|
L
 -14.6%
H
2.3
3.1
|
L
 -2.4%
H
2.0
3.4
|
L
 10.6%
H
0.8
3.4
|
L
 -89.3%
H
0.8
47.3
|
L
H
0.8
47.3
|
L
H
0.8
47.3
|
Voyager Therapeutics Inc |
|
217.4
|
3.9
|
L
 -8.0%
H
3.9
4.3
|
L
 16.7%
H
3.3
4.4
|
L
 24.8%
H
3.0
4.4
|
L
 10.7%
H
2.8
4.4
|
L
 -36.1%
H
2.6
8.3
|
L
 -44.3%
H
2.6
14.3
|
L
 -62.0%
H
2.5
14.3
|
L
H
2.5
31.9
|
Valneva SE - ADR |
|
760.8
|
8.9
|
L
 4.0%
H
8.7
9.1
|
L
 0.1%
H
8.1
9.1
|
L
 -2.7%
H
8.1
12.3
|
L
 43.8%
H
5.4
12.3
|
L
 26.6%
H
3.6
12.3
|
L
 -46.6%
H
3.6
17.8
|
L
H
3.6
67.8
|
L
H
3.6
67.8
|
Wave Life Sciences Ltd. |
|
1,200.6
|
7.5
|
L
 -0.5%
H
7.4
7.6
|
L
 -21.5%
H
7.1
9.9
|
L
 -6.8%
H
7.1
10.6
|
L
 4.4%
H
6.3
10.6
|
L
 47.0%
H
5.3
16.7
|
L
 150.5%
H
3.0
16.7
|
L
 -35.7%
H
1.2
20.0
|
L
H
1.2
56
|
XBiotech Inc |
|
86.6
|
2.8
|
L
 3.7%
H
2.8
2.9
|
L
 -10.1%
H
2.7
3.2
|
L
 -2.7%
H
2.7
3.6
|
L
 -2.1%
H
2.5
3.6
|
L
 -56.4%
H
2.5
8.3
|
L
 -33.2%
H
2.5
10.0
|
L
 -84.8%
H
2.5
21.5
|
L
 -84.2%
H
2.1
26.4
|
Exicure Inc |
|
26.3
|
4.2
|
L
 -3.3%
H
4.0
4.2
|
L
 -25.9%
H
4.0
5.6
|
L
 -44.2%
H
4.0
7.9
|
L
 -61.5%
H
4.0
10.4
|
L
 139.1%
H
1.4
36
|
L
 -53.8%
H
0.3
36
|
L
 -98.5%
H
0.3
424.5
|
L
H
0.3
975
|
Xeris Biopharma Holdings Inc |
|
1,233.7
|
7.6
|
L
 -1.7%
H
7.6
7.8
|
L
 -2.4%
H
7.6
8.0
|
L
 11.7%
H
6.8
8.0
|
L
 66.8%
H
4.3
8.0
|
L
 204.4%
H
2.5
8.0
|
L
 326.8%
H
1.0
8.0
|
L
 65.0%
H
1.0
8.0
|
L
H
1.0
28.0
|
X4 Pharmaceuticals Inc |
|
68.9
|
3.1
|
L
 -9.4%
H
3.1
3.5
|
L
 -18.4%
H
3.0
3.8
|
L
 106.0%
H
1.4
4.8
|
L
 -28.6%
H
1.4
4.8
|
L
 372.3%
H
0.2
6.6
|
L
 162.4%
H
0.2
6.6
|
L
 -61.9%
H
0.2
10.7
|
L
H
0.2
172.2
|
Xencor Inc |
|
594.1
|
8.3
|
L
 -1.0%
H
8.3
8.5
|
L
 2.5%
H
7.9
8.8
|
L
 15.2%
H
6.9
8.8
|
L
 -13.7%
H
6.9
10.2
|
L
 -48.5%
H
6.9
27.2
|
L
 -67.1%
H
6.9
38.2
|
L
 -76.2%
H
6.9
58.3
|
L
 -53.5%
H
6.9
58.3
|
22nd Century Group Inc |
|
6.1
|
1.6
|
L
H
1.6
1.6
|
L
 -7.4%
H
1.6
1.8
|
L
 -33.3%
H
1.6
2.7
|
L
 -90.5%
H
1.6
17.1
|
L
 -99.8%
H
1.6
1570.2
|
L
 -100.0%
H
1.6
1080540
|
L
 -100.0%
H
1.6
4523364
|
L
 -100.0%
H
1.6
4523364
|
YS Biopharma Co Ltd |
|
33.4
|
0.8
|
L
 -3.6%
H
0.8
0.8
|
L
 1.3%
H
0.8
0.9
|
L
 15.7%
H
0.7
0.9
|
L
 -19%
H
0.6
1.5
|
L
 -81.7%
H
0.6
8.5
|
L
 -99.2%
H
0.6
184.4
|
L
H
0.6
184.4
|
L
H
0.6
184.4
|
Zentalis Pharmaceuticals Inc |
|
116.1
|
1.6
|
L
 -1.2%
H
1.6
1.7
|
L
 -4.7%
H
1.6
1.8
|
L
 11.8%
H
1.4
2.1
|
L
 5.9%
H
1.1
2.1
|
L
 -45.6%
H
1.0
5.4
|
L
 -94.3%
H
1.0
31.5
|
L
 -94.1%
H
1.0
87.2
|
L
H
1.0
87.2
|
Zura Bio Ltd - Ordinary Sh... |
|
138.5
|
2.1
|
L
 -3.6%
H
2.1
2.3
|
L
 4.4%
H
2.0
2.3
|
L
 50%
H
1.4
2.3
|
L
 69.1%
H
1
2.3
|
L
 -41.2%
H
1.0
5.1
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
Zai Lab Limited - ADR |
|
3,503.9
|
31.5
|
L
 0.5%
H
30.9
31.5
|
L
 -4.9%
H
28.7
34.0
|
L
 -9.9%
H
28.7
36.8
|
L
 -17.4%
H
28.7
44.3
|
L
 58.6%
H
19.4
44.3
|
L
 -27.3%
H
13.5
54.0
|
L
 -58.7%
H
13.5
193.5
|
L
H
13.5
193.5
|
Apogee Therapeutics Inc. |
|
2,274.8
|
38.2
|
L
 -0.7%
H
37.7
38.8
|
L
 5.0%
H
36
38.8
|
L
 7.9%
H
34.4
38.9
|
L
 -6.9%
H
34.3
47.7
|
L
 -19.2%
H
26.2
63.5
|
L
H
14.2
72.3
|
L
H
14.2
72.3
|
L
H
14.2
72.3
|
Intensity Therapeutics Inc |
|
13.2
|
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
H
0.3
0.3
|
L
 3.7%
H
0.3
0.3
|
L
 -39.1%
H
0.2
0.7
|
L
 -92.9%
H
0.2
4.3
|
L
 -93.0%
H
0.2
11.4
|
L
 -93.0%
H
0.2
11.4
|
L
 -93.0%
H
0.2
11.4
|
Renovaro Biosciences Inc |
|
46.2
|
0.2
|
L
 5.3%
H
0.2
0.2
|
L
 -16.7%
H
0.2
0.2
|
L
 -20%
H
0.2
0.3
|
L
 -35.5%
H
0.2
0.4
|
L
 -67.7%
H
0.2
2.1
|
L
H
0.2
5.3
|
L
H
0.2
5.3
|
L
H
0.2
5.3
|
Elutia Inc - Ordinary Shar... |
|
65.3
|
1.5
|
L
 -18.1%
H
1.5
2.0
|
L
 -32.5%
H
1.5
2.4
|
L
 -23.4%
H
1.5
2.4
|
L
 -19.0%
H
1.5
2.6
|
L
 -63.9%
H
1.5
5.1
|
L
H
1.1
5.2
|
L
H
1.1
5.2
|
L
H
1.1
5.2
|
Tharimmune Inc |
|
15.5
|
2.9
|
L
 -2.0%
H
2.8
3.1
|
L
 -51.3%
H
2.8
5.8
|
L
 135.8%
H
1.1
9.1
|
L
 92.1%
H
1.1
9.1
|
L
 -3.3%
H
1.0
9.1
|
L
 -99.2%
H
0.3
993.8
|
L
H
0.3
1590
|
L
H
0.3
1590
|
Gyre Therapeutics Inc |
|
700.3
|
7.7
|
L
 -2.3%
H
7.7
8.0
|
L
 -0.4%
H
7.0
8.1
|
L
 7.2%
H
6.6
8.4
|
L
 -8.3%
H
6.6
9.2
|
L
 -38.3%
H
6.1
19
|
L
 2.8%
H
5.6
130.5
|
L
 2.8%
H
5.6
130.5
|
L
 2.8%
H
5.6
130.5
|
Lexeo Therapeutics Inc. |
|
287.3
|
5.3
|
L
 1.3%
H
5.2
5.4
|
L
 11.1%
H
4.7
5.4
|
L
 17.4%
H
4.3
5.4
|
L
 37.1%
H
3.6
5.4
|
L
 -51.2%
H
1.5
11.7
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
Korro Bio Inc. |
|
328.7
|
35
|
L
 6.3%
H
32.8
36
|
L
 51.7%
H
20.2
36
|
L
 118.8%
H
14.2
36
|
L
 139.9%
H
11.5
36
|
L
 -14.2%
H
10.3
98
|
L
H
10.3
98
|
L
H
10.3
98
|
L
H
10.3
98
|
Cartesian Therapeutics Inc |
|
267.6
|
10.3
|
L
 1.0%
H
10.1
10.4
|
L
 2.4%
H
9.7
10.8
|
L
 -2.3%
H
9.7
12.3
|
L
 -6.8%
H
9.4
15.6
|
L
 -20.7%
H
8.5
26.5
|
L
 -99.4%
H
8.5
1791
|
L
 -99.5%
H
8.5
5130
|
L
H
8.5
25199.6
|
Elevai Labs Inc. |
|
2.9
|
4.3
|
L
 -2.5%
H
4.3
4.4
|
L
 -24.2%
H
4.3
5.7
|
L
 -34.7%
H
4.3
12.9
|
L
 -43.4%
H
4.3
12.9
|
L
 -99.7%
H
4.3
1837.5
|
L
H
4.3
20796.6
|
L
H
4.3
20796.6
|
L
H
4.3
20796.6
|
Spyre Therapeutics Inc. |
|
1,003.9
|
16.6
|
L
 -0.1%
H
16.3
17.1
|
L
 0.8%
H
16.1
17.6
|
L
 9.6%
H
14.7
17.8
|
L
 -2.1%
H
13.9
19.2
|
L
 -40.6%
H
10.9
40.3
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
Neurogene Inc |
|
270.6
|
19.0
|
L
 -2.5%
H
18.7
19.8
|
L
 2.6%
H
18.4
20.7
|
L
 -10.7%
H
18
21.7
|
L
 -13.2%
H
14.7
23.9
|
L
 -45.8%
H
6.9
74.5
|
L
 33.7%
H
6.9
74.5
|
L
 33.7%
H
6.9
74.5
|
L
 33.7%
H
6.9
74.5
|
Cg Oncology Inc. |
|
2,522.3
|
33.1
|
L
 -1.8%
H
32.1
33.8
|
L
 23.3%
H
26.2
34.7
|
L
 33.1%
H
23.7
34.7
|
L
 22.9%
H
23.7
34.7
|
L
 -13.1%
H
14.8
40.4
|
L
H
14.8
50.2
|
L
H
14.8
50.2
|
L
H
14.8
50.2
|
FibroBiologics Inc |
|
23.0
|
0.6
|
L
 -3.5%
H
0.5
0.6
|
L
 -6.8%
H
0.5
0.6
|
L
 -5.2%
H
0.5
0.6
|
L
 -42.7%
H
0.5
1.0
|
L
 -73.7%
H
0.5
4.4
|
L
H
0.5
55
|
L
H
0.5
55
|
L
H
0.5
55
|
Kyverna Therapeutics Inc. |
|
163.9
|
3.8
|
L
 -2.8%
H
3.7
3.9
|
L
 2.2%
H
3.6
4.1
|
L
 17.0%
H
2.8
4.1
|
L
 11.8%
H
2.5
4.6
|
L
 -48.4%
H
1.8
7.9
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
Metagenomi Inc. |
|
69.8
|
1.9
|
L
H
1.9
1.9
|
L
 6.9%
H
1.7
2.0
|
L
 -3.1%
H
1.7
2.1
|
L
 7.5%
H
1.4
2.9
|
L
 -31.6%
H
1.2
4.9
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
Tevogen Bio Holdings Inc. |
|
171.1
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 -4.4%
H
0.9
1.0
|
L
 -3.3%
H
0.9
1.1
|
L
 -39.2%
H
0.8
1.4
|
L
 107.1%
H
0.3
3.1
|
L
H
0.3
21.1
|
L
H
0.3
21.1
|
L
H
0.3
21.1
|
NeOnc Technologies Holding... |
|
160.8
|
8.3
|
L
 1.0%
H
8.1
8.5
|
L
 12.4%
H
6.8
8.8
|
L
 74.1%
H
4.7
8.8
|
L
 12.4%
H
3.2
8.8
|
L
H
3.2
8.8
|
L
H
3.2
8.8
|
L
H
3.2
8.8
|
L
H
3.2
8.8
|
LENZ Therapeutics Inc. |
|
1,122.6
|
39.4
|
L
 -0.7%
H
39.3
40.6
|
L
 1.9%
H
38.4
42.8
|
L
 13.5%
H
34.9
42.8
|
L
 23.2%
H
27.8
42.8
|
L
 65.4%
H
16.5
42.8
|
L
 57.9%
H
14.4
42.8
|
L
 57.9%
H
14.4
42.8
|
L
 57.9%
H
14.4
42.8
|
Boundless Bio Inc. |
|
25.7
|
1.2
|
L
H
1.1
1.2
|
L
 2.7%
H
1.1
1.2
|
L
 6.5%
H
1.1
1.2
|
L
 -2.5%
H
1
1.3
|
L
 -63.3%
H
1
4.7
|
L
H
1
14.7
|
L
H
1
14.7
|
L
H
1
14.7
|
Contineum Therapeutics Inc... |
|
343.2
|
12.2
|
L
 0.9%
H
11.9
12.5
|
L
 17.1%
H
10.2
13.3
|
L
 89.2%
H
6.2
13.3
|
L
 157.7%
H
3.6
13.3
|
L
 -26.5%
H
3.4
20.3
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
Eupraxia Pharmaceuticals Inc |
|
187.3
|
5.2
|
L
 -1.1%
H
5.2
5.3
|
L
 -2.8%
H
5.2
5.5
|
L
 -1.0%
H
5.0
5.6
|
L
 32.2%
H
3.9
6.2
|
L
 105.1%
H
2.2
6.2
|
L
H
2.2
6.2
|
L
H
2.2
6.2
|
L
H
2.2
6.2
|
Entero Therapeutics Inc. |
|
3.8
|
2.4
|
L
 -9.1%
H
2.4
2.6
|
L
 4.8%
H
2.1
3.0
|
L
 117.3%
H
1.5
3.0
|
L
 53.2%
H
1.1
3.0
|
L
 102.5%
H
0.8
3.0
|
L
 -71.3%
H
0.6
9.5
|
L
 -71.3%
H
0.6
9.5
|
L
 -71.3%
H
0.6
9.5
|
Artiva Biotherapeutics Inc |
|
66.9
|
2.7
|
L
 -11.3%
H
2.7
3.2
|
L
 -13.0%
H
2.7
3.7
|
L
 -0.7%
H
2.5
3.7
|
L
 30.5%
H
1.5
3.7
|
L
 -77.2%
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
MBX Biosciences Inc. |
|
377.6
|
11.2
|
L
 3.1%
H
10.6
11.3
|
L
 -25.5%
H
10.6
15.2
|
L
 -7.6%
H
10.6
15.4
|
L
 -1.1%
H
9.4
15.9
|
L
H
4.8
27.5
|
L
H
4.8
27.5
|
L
H
4.8
27.5
|
L
H
4.8
27.5
|
BioAge Labs Inc. |
|
178.5
|
5.0
|
L
 -2.2%
H
4.9
5.1
|
L
 1.0%
H
4.6
5.1
|
L
 15.0%
H
4.3
5.1
|
L
 11.9%
H
4.1
5.1
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
OnKure Therapeutics Inc. -... |
|
35.4
|
2.6
|
L
 -0.4%
H
2.5
2.7
|
L
 -4.7%
H
2.5
3.0
|
L
 28.4%
H
1.9
3.0
|
L
 -9.0%
H
1.9
3.2
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
CAMP4 Therapeutics Corp. |
|
-
|
1.9
|
L
 15.2%
H
1.7
1.9
|
L
 25%
H
1.4
1.9
|
L
 32.9%
H
1.3
1.9
|
L
 -1.0%
H
1.3
2.0
|
L
 -17.4%
H
1.3
2.2
|
L
 -17.4%
H
1.3
2.2
|
L
 -17.4%
H
1.3
2.2
|
L
 -17.4%
H
1.3
2.2
|
Upstream Bio Inc. |
|
1,003.3
|
18.6
|
L
 -0.6%
H
18.4
18.9
|
L
 8.6%
H
16.7
21.0
|
L
 16.3%
H
15.6
21.0
|
L
 65.1%
H
9.8
21.0
|
L
H
5.1
29.5
|
L
H
5.1
29.5
|
L
H
5.1
29.5
|
L
H
5.1
29.5
|
Medicus Pharma Ltd |
|
38.9
|
2.1
|
L
 -0.5%
H
2.0
2.1
|
L
 7.2%
H
1.8
2.1
|
L
 5.6%
H
1.8
2.5
|
L
 -24.6%
H
1.8
3.7
|
L
 -69.1%
H
1.8
8.9
|
L
 -69.1%
H
1.8
8.9
|
L
 -69.1%
H
1.8
8.9
|
L
 -69.1%
H
1.8
8.9
|
Telix Pharmaceuticals Ltd.... |
|
3,092.9
|
9.2
|
L
 2.1%
H
9.1
9.3
|
L
 -3.3%
H
8.9
9.4
|
L
 -18.5%
H
8.9
12.6
|
L
 -44.9%
H
8.9
18.5
|
L
H
8.9
30.4
|
L
H
8.9
30.4
|
L
H
8.9
30.4
|
L
H
8.9
30.4
|
Palvella Therapeutics Inc. |
|
620.7
|
56.1
|
L
 2%
H
54.4
56.8
|
L
 3.6%
H
50.8
58.2
|
L
 37.2%
H
40.2
58.2
|
L
 120.9%
H
20.2
58.2
|
L
 312.7%
H
11.2
58.2
|
L
 312.6%
H
11.2
58.2
|
L
 312.6%
H
11.2
58.2
|
L
 312.6%
H
11.2
58.2
|
Sionna Therapeutics Inc. |
|
1,045.2
|
23.7
|
L
 9.5%
H
20.6
24
|
L
 -3.8%
H
20.6
26.5
|
L
 34.0%
H
17.1
26.5
|
L
 37.5%
H
13.5
26.5
|
L
H
7.3
26.5
|
L
H
7.3
26.5
|
L
H
7.3
26.5
|
L
H
7.3
26.5
|
Zenas Biopharma Inc. |
|
906.2
|
21.5
|
L
H
21.3
22.2
|
L
 34.5%
H
16.1
22.2
|
L
 47.1%
H
14.4
22.2
|
L
 93.5%
H
8.9
22.2
|
L
 105.5%
H
8.9
22.2
|
L
 105.5%
H
8.9
22.2
|
L
 105.5%
H
8.9
22.2
|
L
 105.5%
H
8.9
22.2
|
Propanc Biopharma Inc |
|
-
|
1.9
|
L
 -4.6%
H
1.8
2.1
|
L
 -38.4%
H
1.8
3.1
|
L
 -35.2%
H
1.8
9.4
|
L
 -35.2%
H
1.8
9.4
|
L
 -35.2%
H
1.8
9.4
|
L
 -35.2%
H
1.8
9.4
|
L
 -35.2%
H
1.8
9.4
|
L
 -35.2%
H
1.8
9.4
|